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Zusammenfassung  
 
In der vorliegenden Arbeit haben wir uns die Frage gestellt, ob selektive 
virusähnliche Partikel (VLP) mit einem fluoreszierenden Protein ausgestattet 
werden können, um damit entsprechende Zielzellen identifizieren zu können. 
Unsere Arbeitsgruppe hat in der Vergangenheit gezeigt, dass VLP, welche vom 
Moloney Mäuse Leukämie Viruses (MoMLV) abstammen, mit Immunmodulatoren 
oder Zytokinen der Wahl ausgestattet werden können. Derartige VLP können 
polyklonale oder aber auch eine immunspezifische T-Zell Antwort induzieren. 
Partikel, die zusätzlich mit fluoreszierenden Proteinen ausgestattet werden und die 
einen Liganden für einen entsprechenden Oberflächen-Rezeptor exprimieren, 
können dazu verwendet werden, um entsprechende Zielzellen zu detektieren. In 
der vorliegenden Arbeit wurde das grünfluoreszierende Protein (GFP) mit dem 
Matrix Protein (MA) des MoMLV genetisch verknüpft. MA::GFP wird in 
transfizierten Zellen in den sogenannten “lipid rafts“ angereichert. Als 
Produzentenzelllinie wurden die mit dem MA::GFP stabil transfizierten HEK-293 
Zellen etabliert. Die transiente Transfektion der HEK-293 MA::GFP Zellen mit 
Kapsidproteinen führte zur Sekretion von fluoreszierenden Partikeln, welche wir 
als Fluorosomen (FS) bezeichnen. FS wurden aus den Überständen der HEK-293 
MA::GFP Zellen mittels Ultrazentrifugation angereichert und mit entsprechenden 
Zielzellen inkubiert. Die derartig behandelten Zellen wurden anschließend mittels 
Durchflusszytometrie analysiert. Die FS wurden mit GPI-verankerten Liganden 
dekoriert was in transient transfizierten HEK-293 Zellen erreicht wurde. FS die mit 
IL-2::GPI ausgestattet wurden, konnten erfolgreich zum Nachweis von HT-2 Zellen 
verwendet werden, die den Maus IL-2 Rezeptor konstitutiv auf ihrer Zelloberfläche 
exprimieren. Des Weitern konnte gezeigt werden, dass FS auch für den Nachweis 
von IL-2 Rezeptorkomponenten, exprimiert auf HEK-293 Zellen, geeignet sind. Es 
konnte auch gezeigt werden, dass auf FS auch komplexe Strukturen verankert 
werden können, indem wir einen kompletten IL-2 Rezeptor transient transfiziert 
haben um membranständiges IL-2::GPI nachweisen zu können. Des Weitern 
konnte gezeigt werden, dass IL-2::GPI FS und IL-7::GPI FS, aktivierte humane T-
Lymphozyten des peripheren Blutes identifizieren können. Schlussendlich wurde 
auch der Nachweis erbracht, dass maligne Zellen von Patienten mit chronischer 
lymphatischer Leukämie mit IL-2::GPI FS identifiziert werden können. Die 
Schlussfolgerung dieser Arbeit ist, dass FS nützliche Hilfsmittel darstellen, die zum 
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Nachweis von mono- oder polyvalenten immunologischen Rezeptor/Ligand 
Interaktion genutzt werden können.  
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Abstract  
 
Moloney murine leukemia virus (MoMLV) derived particles decorated with 
immunomodulators and cytokines can be used to influence polyclonal and antigen-
specific T cell responses. By targeting fluorescent dyes to these particles, the 
interaction between the particle-borne ligands and their respective receptors on 
the cell surface of target cells can be visualized. For that purpose, the green 
fluorescent protein (GFP) was fused to the matrix protein (MA) of MoMLV, which 
leads to lipid raft targeting and in consequence to the incorporation into virus-like 
particles (VLP). In a first step, HEK-293 cells stably transfected with MA::GFP 
were established as VLP producer cells. Upon transfection with MoMLV core 
proteins the production of fluorescent VLP- designated as fluorosome (FS) - was 
induced. FS were purified from the supernatant of producer cells by 
ultracentrifugation and used for staining of various target cells in a similar way as 
antibodies in flow cytometric analyses. Decoration with specific ligands was 
achieved by co-transfection of GPI-anchored molecules into the producer cell. In 
proof of principle experiments, FS decorated with IL-2::GPI were used to stain 
murine HT-2 cells, which constitutively express the murine IL-2 receptor. In these 
experiments the staining capacity of FS was evaluated. Furthermore IL-2::GPI FS 
were used to stain HEK-293 cells transfected with IL-2 receptor components and 
vice versa. It was also shown that FS decorated with IL-2::GPI or IL-7::GPI can 
stain human peripheral blood mononuclear cells (PBMC) from healthy individuals 
and chronic lymphatic leukemia (CLL) patients. In conclusion FS with membrane-
targeted fluorescent proteins are useful tools for assessing mono- and multi-
subunit immune-receptor/ligand interactions. 
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1. Introduction  
 
 
In the past it was shown that virus-like particles (VLP) can be used as innovative 
platform for the generation of immuno-stimulatory (immunosomes) and immuno-
modulatory (anergosomes) particles. (1-3) Studies using immunosomes, 
demonstrated the stimulation of T cells with cell-free VLP expressing the primary 
signal in form of a surrogate TCR/CD3 ligand (OKT3scFv) and the costimulatory 
second signal CD80, which lead to polyclonal activation of T cells. (1) Further 
studies incorporated human interleukin-2 (hIL-2), hIL-4 or human granulocyte-
macrophages colony-stimulating factor (hGM-CSF) but also murine IL-2 into VLP 
which lead to stimulation of T cells and monocytes. (2) The experiments in the 
past concentrated predominantly on immunoreceptor effects on cells of the 
immune system, which lead us to speculate if it would be possible to visualize 
these interactions. First we tested if it would be possible to target recombinant 
fluorescent proteins of Cnidarian origin corresponding to the green fluorescent 
protein (GFP) of Aequorea victoria or mcherry of Discosoma sp. (4-6) to the 
membrane of virus-like particles (VLP). Targeting of the fluorochromes was 
achieved by fusing them to the matrix protein (MA) of Moloney murine leukemia 
virus (MoMLV). (7, 8) The MA protein gets posttranslationally modified followed by 
targeting into the plasma membrane, with fused GFP or mcherry. This forms the 
basis for the production of our fluorescent VLP or “fluorosomes” (FS) based on 
MA::GFP (green) or MA::mCherry (red). (9, 10) Stably transfected human 
embryonic kidney (HEK)-293 cells expressing MA::GFP or MA::mCherry which is 
an immortalized cell type have been used as producer cell. The decoration of FS 
with molecules of choice can be achieved by fusion of the respective ectodomains 
with human Fc gamma receptor III (CD16b), which possesses a well-described 
glycosyl phosphatidyl inositol (GPI) anchor acceptor sequence. (2) The constructs 
used in this report are membrane bound human (h) interleukin (IL)-2::GPI, hIL-
7::GPI and hIL-2 receptor–components. (2) Particle production was induced by co-
expression of gag/pol (OGP) from MoMLV. (1) After purification, the FS can be 
used for staining of corresponding target cells.  
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1.1  Transport of membrane proteins  
 
Protein translation and transport in the cell is segmented in two main pathways. 
The first pathway is the secretory pathway: Proteins are secreted to the 
endoplasmic reticulum (ER) already during translation. (11, 12) They pass the ER 
and the Golgi-network and some of them become post-translationally modified 
during this translocation. (11, 12) These modifications are for example 
glycosylation, acetylation, palmitoylation and myristoylation. (13, 14) After passing 
the Golgi-network members can either be secreted to the extracellular space to 
the lysosome or to the plasma-membrane. (11, 12) The second group of proteins 
is involved in cytosolic processes or organelle biogenesis. (11, 12) Proteins that 
are involved in organelle biogenesis lead to the formation and maturation of 
organelle components like membranes of the nucleus or the mitochondrion and 
cytosolic proteins are mainly involved in cellular enzymatic processes. (11, 12)  
Generally, the first and most important step of protein targeting is the translation of 
the signal peptide. (11, 15) The coding mRNA contains on the 5`part a leader 
signal, which directs the protein in the cell. (11, 15) The leader peptide of 
transmembrane type I proteins is a highly hydrophobic sequence which is thus 
anchored into the ER membrane. (12, 15) The signal peptide is recognized by a 
protein complex that cuts this leader sequence and transports the translated 
protein into the lumen of the ER (Fig. 1). This complex is called the translocon. 
(15) The translocon consists of a signal recognition particle (SR) and a signal 
peptidase (SPC) that removes the leader sequence. (12, 15)  
Due to the mechanism described above the translated protein is transported into 
the ER lumen. During this process the amino terminal part (N-terminus) is the first 
to be translocated into the ER lumen. (12, 15) These proteins (Fig.1) contain an 
approximately 22 amino acid (aa) long stop-transfer membrane anchor-sequence 
at the carboxy terminal part (C-terminus). (11) This is the signal that stops the 
transfer of the protein into the lumen of the ER. (11) Afterwards, the ribosome is 
disconnected from the translocon. (11) The fully translated protein is thereby 
anchored into the ER membrane. (11) Consequently, the C-terminus projects to 
the cytosol (outside of the ER lumen). (11, 12)  
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Figure 1. The transport of transmembrane proteins to the endoplasmic reticulum (ER). The 
translocon consists of Signal recognition particle (SRP), the SRP receptor (SR), Sec61 which form 
the tunnel, TRAM is required for some proteins and the signal peptidase (SPC). (15) 
from: Ramanujan S. Hegde and Sang-Wook Kang; (2008) J Cell Biol. 182(2): 225–232 
 
 
1.1.1 Post-translational modification  
 
The ER and Golgi-network are responsible for post-translational modifications of 
proteins. (12) Post-translational modifications include generation of disulfide 
bonds, controlled folding of proteins with help of chaperons, attachment of 
carbohydrates, cleavage of pre-forms, connection to protein complexes and lipid 
modifications. (11, 15) The main part of the post-translational modifications occurs 
in the ER. (11) The environment in the ER facilitates the reduction of sulfide 
groups to their oxidized conformation, which leads to the generation of disulfide 
bonds. (11) Disulfide bonds are very important for protein stability and also for the 
formation of protein complexes. (11, 15) Furthermore, the ER contains numerous 
chaperons that are responsible for the formation of correct protein conformation. 
Some of these chaperons are for example the Protein Disulfide Isomerase (PDI), 
the heat shock protein 70 (Hsc70), Calnexin, Calreticulin and also the Peptidyl-
Prolyl-Isomerase. (11, 15) The reassembling of protein complexes also takes 
place in the ER. (11, 12, 15) The next maturation step for a protein is the transport 
from the ER to the Golgi-network. Only appropriately folded proteins are able to 
leave the ER and enter into the Golgi-network for further modification. (11, 15, 16) 
Proteins with the wrong conformation form complexes with ER chaperons and are 
retained in the ER. (11, 13, 15, 16) These incorrectly folded proteins are 
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afterwards transported back from the ER into the cytosolic space and cleaved by 
the proteasome. (11, 13, 15, 16) Also incorrect translation processes lead to the 
formation of defective ribosomal products (DRiPs). (17) DRiPs of cytosolic 
proteins, are directly proteolysed by the proteasome. Secretory proteins, which are 
translated in the ER are transported back by the translocon into the cytosol 
followed by degradation in the proteasome. (17) The proteolysed peptides are 
transported into ER due to TAP and become then loaded onto MHC I. (17) 
The inositol requiring enzyme 1 (IRE1) an ER-resident transmembrane protein is 
especially important. (11, 15, 16) This protein is responsible for the recognition of 
unfolded proteins. (11) IRE1 binds unfolded proteins and leads to splicing of the 
mRNA of the transcription factor HAC1. (11, 15, 16) HAC1 then enhances 
synthesis of chaperons for the refolding, when wrongly folded proteins 
accumulate. (11) If no proper folding can be achieved, proteins are ubiquitinylated, 
returned to the cytosol and cleaved by the proteasome. (11, 15, 16) Protein 
transport between the ER and cis-Golgi-network is mediated by so called shuttle 
vesicles. (11, 16) These shuttle vesicles contain the KDEL receptor. (11) All 
proteins containing a KDEL signal sequence are returned from cis- Golgi-network 
back to the ER. (11, 12, 15)  
 
1.1.2 GPI-anchoring of type I membrane proteins  
 
Transmembrane proteins are classified into two different groups dependent on 
their orientation and architecture in the plasma membrane (Fig.3). (18-20) In type I 
membrane proteins the N-terminus is localized extracellularly, while the C-
terminus is in the cytosol. Type I membrane proteins typically have also a 
hydrophobic transmembrane domain. (19) Type II membrane proteins reveal the 
opposite orientation of C- and N-terminus relative to the plasma membrane 
compared to type I proteins. (15, 19) In general the orientation of the membrane 
proteins is achieved by the presence and localization of the protein leader signal 
sequence. (19)  
As mentioned above, type I membrane proteins contain the leader signal 
sequence at the freshly synthesized N-terminus (Fig.2). (11, 15) The leader is 
recognized and removed by the SPC of the translocon. (15) The stop-transfer 
signal leads to ER transfer inhibition of the newly synthesized protein retaining it in 
the ER membrane. The translated type I membrane protein possesses a 
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characteristic C-terminal 21-26 amino acid (aa) length anchor consisting of a 
hydrophobic α-helix which anchors it to the ER membrane. (11, 15) The signal 
sequence of type II membrane proteins is not cleaved by SPC, instead it 
generates a loop relative to the tunnel proteins (Sec61) of the translocon which 
serves as anchor. (11, 15, 19) The consequence of this connection to the 
translocon is the opposite orientation of type II membrane proteins in respect to N- 
and C- terminus. (11, 15)  
 
 
 
Figure 2. The localization of type I and type II proteins in the translocon.  
adapted from: Ramanujan S. Hegde and Sang-Wook Kang; (2008) J Cell Biol. 182(2): 225–232 
 
 
Further classifications include also type III and type IV transmembrane proteins. 
(19) The type III proteins (Fig.3) have a start-stop transfer sequence, the location 
of the proteins is dependent on the polarization of the α-helical domain that is 
anchored in the membrane. (19) Type III membrane proteins possess a non 
cleavable leader sequence like type I membrane proteins, but the electrical charge 
orientation is opposite to type II proteins. This orientation is reached through the 
polarized charges of the anchoring α-helix domain. (19) The α-helix of type II 
membrane proteins, is negatively charged relative to the N-terminus. (19) 
However, type III proteins, α-helical domain is positive in N-terminal direction. (19) 
The constitution of the membrane protein is affected through the charges within 
the α-helix. (19)  
Type IV membrane proteins contain more than one α-helical domain (Fig.3), 
spanning the cell membrane. (19) These transmembrane proteins are 
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characterized by the numbers of the membrane spanning-domains. (15, 19) If the 
number of the spanning-domains is odd, the orientation of termini is opposite on 
the different sides related to the membrane (common type of structure 7-
membrane passage), whereas to an even number the protein termini are arranged 
in the same direction (common type of structure 12-membrane passage). (15, 19) 
GPI-anchored proteins belonging to type V membrane proteins are connected 
immediately after translation to a preformed GPI-anchor. The difference between 
α-helix anchored type I transmembrane proteins and GPI–anchored type V 
transmembrane proteins, except of their anchoring, is the signal during the 
translation that implicates the disconnection from the α-helix to the GPI-anchor. 
(11) The translated protein is associated with the ER membrane. (11) The N-
terminus of the polypeptide is located in the ER lumen, the C-terminal α-helix is 
attached to the ER membrane and possesses the GPI-anchor attachment signal 
sequence which is required for the connection to the GPI-anchor. (11) An ER-
endoprotease recognizes this sequence and couples it to a preformed GPI-anchor. 
(11) This ER endoprotease segregates by proteolysis the polypeptide from the 
hydrophobic membrane α-helix anchor and associates the free C-terminus of the 
protein with the free amino group of the GPI-anchor. (11, 21) This modification 
results in targeting of GPI-anchored membrane proteins into the lipid rafts. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The order of transmembrane proteins.  
from: Spiess M. (1995) FEBS Lett. 369:76 
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The GPI-anchor comprises a strictly conserved glycan core (mannose(α1-2) 
mannose(α1-6)mannose(α1-4)glucosamine(α1-6)myc-inositol). (22, 23) Moreover, 
numerous combinations of residues can be connected to the conserved glycan 
core molecule, which enhance the specificity of the anchoring, which is important 
for different receptors. (22, 24-26) The GPI-anchored protein is coupled through 
phosphoethanolamine to the C-termini of the GPI-anchor (Fig.4). (22, 24)  
The connection of GPI-anchored proteins can be verified by incubation with 
phosphatidylinositol phospholipase C (PI-PLC) from B. thuringiensis. The 
consequence of the PI-PLC treatment is the release of GPI-anchored proteins. 
(11) The PI-PLC, that was purified from several bacteria (Bacillus cereus, 
Staphylococcus aureus, Clostridium novyi and also Bacillus thuringiensis), is able 
to cleave the bond between the glycerin and the inositol within the GPI-anchor (22, 
27) 
 
 
 
Figure 4. Typical structure of the GPI-anchor. The three domains of the GPI-anchor are: (I) 
(black) the glycan core backbone ; (II) (blue) phospholipid tail and (III) (red) phosphoethanolamine 
linker. The blue residues are variable.  
from: Paulick MG, Bertozzi CR (2008) Biochemistry Review 47(27):6991-7000 
 
 
1.1.3 Glycosylation in endoplasmic reticulum and Golgi-network 
 
Glycosylation of proteins is happening in the Golgi-network and is also 
implemented in the ER. However, the first important glycosylation steps take 
already place in the ER. (11) During translation in the ER, proteins become N-
Calin Manta  Introduction 
16 
glycosylated. (11, 14) The glycosylation process is distinguished in N- or O-
glycosylation. (11) During the O-glycosylation sugar residues are added 
consecutively to the protein and during the N-glycosylation process one 
oligosaccharide complex of different sugars is transferred to the receiver protein. 
(12, 14, 15) The sugar residues in the oligosaccharide complex are linked through 
N-glycosylic links. Some of the sugars are removed during the process of N-
glycosylation, after the connection to the protein. (12, 14) The transfer of the 
oligosaccharide complex is dependent on the amino acid (aa) sequence of the 
protein (Asn-X-Ser or Asn-X-Thr, X is optional aa except of prolin). (11, 14, 28, 29) 
The oligosaccharide complex is connected to the asparagine of the protein. (11, 
14) The oligosaccharide complex is composed of glucose (Glc)3, mannose (Man)9 
and N-acetylglucosamine (GlcNAc)2. (11, 14) The three glucose (Glc)3 residues 
are removed during the transport process in the ER, so that only (Man)8 (GlcNAc)2 
enter in the cis-Golgi-network. (11, 14) The oligosaccharide complex interacts with 
chaperons before entering into the Golgi-network, the right folding of the protein is 
controlled in this way. (11, 12, 14, 15)  
The last post translational modifications of proteins happen in the Golgi-network. 
(12) The Golgi-network is segmented in three compartments, the cis, medial and 
trans-Golgi-network. (15) These compartments contain different specific enzymes 
that lead to addition or removal of monosaccharides. (11) The N-glycosylated 
protein ((Man)8 (GlcNAc)2 ) from the ER is transported into the cis-Golgi-network. 
(11) (14) The three mannose (Man)3 residues are removed in the cis-Golgi-
network, which leads to a new oligosaccharide structure (Man)5 (GlcNAc)2. (11, 14) 
Afterwards, the N-glycosylated protein is transported to the trans-Golgi-network, 
were several conversions of the connected sugar residues of the oligosaccharide 
complex take place. (11, 14) These conversions include the removal of (Man)2 and 
the addition of three N-acetylglucosamine (GlcNAc)3 residues and one fucose 
(Fuc)1 molecule. (11, 12, 14) The new structure of the connected oligosaccharide 
complex is an assembly of (GlcNAc)3 (Man)3 (GlcNAcGlc)2 (Fuc)1. (11, 14) The 
enzymes in trans-Golgi-network perform two additional modifications in which 
three galactose (Gal)3 and three N-acetylneuraminic acid (NeuN5Ac)3 are 
connected with each of the three galactose (Glc)3. (11, 12, 14)  
GPI-anchored proteins are sorted, after all these maturation steps in the ER and 
the Golgi-network towards the plasma membrane. (11)  
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1.2  Lipid rafts - gateways for fluorosomes 
 
The production of the fluorosomes (FS) and their decoration with GPI-anchored 
proteins is lipid raft dependent. Lipid rafts of the producer cells are meeting, 
anchoring, budding and secretion points for the decorated FS. (30)  
The common definition for lipid rafts is that they are highly ordered cholesterol and 
sphingolipid enriched regions in the plasma membrane (14, 31, 32), organized and 
separated from the rest of the plasma membrane as microdomains. (33) The 
sphingolipids contain palmitol as main component, which is saturated. (21) The 
saturated hydrocarbons allow a very tightly packing of the self assembling lipid 
rafts in the bilayer. (22) The task of the cholesterol is to fill the empty space 
between the sphingolipids and this leads to a higher hydrophobicity and a high 
degree of order. (22, 31) The cholesterol is essential for the function and the 
formation of lipid rafts. Due, to this saturated components the lipid rafts are less 
fluid in comparison to the surrounding. (22, 31) Lipid rafts, are very important for 
cellular functions including trafficking of vesicles, signal transduction (22, 31, 32) 
and also as gateways for enveloped viruses. (1, 2) Further important 
characteristics of lipid rafts are their insolubility to detergents at 4°C. The condition 
for the detection of lipid raft targeted, GPI-anchored proteins is, the application of 
non-ionic detergent, for example Triton X-100 under strict low temperature (4°C) 
conditions. (22, 31, 32) Under this condition proteins associated with lipid rafts 
remain insoluble and can be isolated, by isopycnic sucrose gradient centrifugation. 
(22, 34)  
 
1.3  Moloney murine leukemia virus as platform for fluorosomes 
 
The ecotropic Moloney murine leukemia virus (MoMLV) is an enveloped retrovirus 
having two copies of viral RNA. (35-38) The advantages of MoMLV are, it´s easy 
handling, its tropism which makes it non-pathogenic for humans and the fact that it 
permits long-term transgenic expression in transduced cells. (35) The MoMLV 
genome contains three components, the core proteins (gag), the polymerase/ 
integrase (pol) and the envelope (env). (36, 37) The env encodes two polypeptides 
which are derived from a single precursor gPr80env which is proteolytically cleaved, 
into the 17-kDa transmembrane polypeptide (TM) and the 70-kDa surface 
glycoprotein protein (SU). (38-43) Th
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up the spikes on the virus particle. (39-42) Palmitoylation is required for the 
targeting of the ENV proteins to the cell surface (38, 44-48) The SU proteins 
recognize respective receptor Ram-1 on the cell surface of the target cell (49, 50), 
the consequence is a conformational change in the spike, leading to membrane 
fusion and allowing virus-entry into the cell. (39, 51-53) MoMLV can be classified 
into five subgroups, depending of the SU protein. (39) MoMLV is a mouse and rat 
infectious virus that induces leukemia. (39, 54) Among others it was discovered 
that MoMLV has a leukemia inducing effect in p53 -/- mice, which developed 
tumors much faster as p53 +/- mice. (54). 
The core proteins, also called “structural GAG” proteins have one common 
precursor the p65gag. (55-59) The encoded structural proteins are the capsid 
protein (CA) p30, the nucleocapsid (NA) p10, the matrix protein (MA) p15 and p12. 
(55, 56, 60, 61)  
The capsid proteins require myristylation at the N-terminal glycine, for targeting to 
the plasma membrane and for virus budding. (62-65) The pol genes encode the 
transcription components, the reverse transcriptase and the integrase of the virus. 
(60, 61)  
In our experiments we used a vector system encoding only gag and pol (OGP) 
which upon transfection into the producer cell leads to the budding of non 
infectious virus-like particles (VLP). As a producer cell we used the human 
embryonic kidney cells, HEK-293, which is an embryonic kidney epithelial cell line 
transformed by sheared DNA of adenovirus type 5 (66) The transfection of HEK-
293 cells with gag/pol OGP, leads to budding of the virus particles from the cell 
membrane. (1, 2, 35) The meeting point, but also the sites of budding for the 
MoMLV proteins are the lipid rafts of the plasma membrane. (1, 2, 35) 
 
 
1.4  Interleukin-2 function 
 
Interleukin-2 (IL-2) was initially discovered as a 15 kDa glycoprotein, in culture 
medium of lymphocytes that were stimulated with antigen or mitogen (67, 68) 
Because of it’s T cell stimulating capacity it was named T cell growth factor 
(TCGF). The production of IL-2 requires an antigen presenting cell (APC) which 
activates T cell. APC takes up the pathogen, this leads to the presentation of the 
antigen on the MHC (in case of CD4+ T cells on MHC II). (69, 70)  
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The APC migrates into the lymph node where it meets naive T cells and B cells. T 
cell and APC go through an initial recognition phase of the MHC and the peptide 
through the TCR (Signal 1). (69, 70) The recognition of the MHC and the peptide 
is the first step for the IL-2 activation. The second signal (Signal 2) is the T cell 
CD28 Receptor and the APC CD80 (B7.1) ligand that enhances and contributes to 
signal 1. (69, 70) Both signals are required for sustained IL-2 induction in T cells, 
which leads to activation and proliferation. (67)  
The Lck kinase (Src family) which is coupled to the CD4 molecule (co-receptor) 
phosphorylates the immunoreceptor tyrosine-based activation motif (ITAM) 
domains of the CD3 and the ζ chains. (69, 70) ZAP 70 (Syk family) phosphorylates 
LAT adapter protein which is a signalling platform. (69, 70) Three main events, are 
activated from the phosphorylated LAT protein, the MAP kinase cascade, the 
opening of the Ca2+ channels and the recruitment of diacylglycerol (DAG). (69, 70) 
The mentioned events lead to the recruitment of transcription factors which initiate 
IL-2 transcription. (69, 70) The first pathway, the MAP kinase cascade involving 
the upstream factors Grb2 and Sos (heterodimer), leads to phosphorylation of 
monomeric Ras protein. (69, 70) Ras, which is connected to guanine di-phosphate 
(GDP) receive a further phosphate, the product of the phosphorylation is 
guanosine tri-phosphate (GTP). (69, 70) Activated Ras together with Raf 
phosphorylates MEK, this leads to ERK phosphorylation and to activation of ELK, 
that enters into the nucleus and leads to the translation of the protein fos. (69, 70) 
Fos is one part of the heterodimeric transcription factor AP1, whose second part is 
the phosphorylated Jun. (69, 70) The activation of Jun, is also due to Ras 
MAPkinase pathway (JNK instead of ERK). (11, 69, 70)  
The second and third pathways are connected through PLCγ1, a protein which is 
also recruited to LAT and is phosphorylated by ZAP70 and Itk. (69, 70) PLCγ1 
hydrolyses the phosphatidylinositol-2-phosphate (PIP2) to inositol 3 phosphate 
(IP3) and Diacylglycerol (DAG). (11, 69, 70) IP3 leads to an increase of cytosolic 
calcium (Ca2+)-ions, due to the opening of the Ca2+-channels in the smooth ER 
and in the cytoplasma membrane. (69, 70) The increasing amount of Ca2+ leads to 
recruitment of the heterodimeric calmodulin and calcineurin. (69, 70) These 
complexes activate cytoplasmic nuclear factor of activating T cells (NFAT). (11, 
69, 70) DAG accumulates in the plasmamembrane and recruits PKC. (11) PKC 
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has an influence on decomposition of the inactive heterotrimer NFκB to the active 
heterodimer that is able to enter into the nucleus. (11, 69, 70)  
The transcription factor complex comprised of NFκB (heterodimer), NFAT and 
AP1 activates the transcription of IL-2 mRNA. (69, 70) The IL-2 transcription is 
initiated by activating signal of the APC. Moreover, upon activation the IL-2 
receptor α-chain (CD25) is de novo expressed. This contributes to the formation of 
the high affinity receptor (KD=10-11). (67, 71-74) The IL-2 receptor adapts to a 
trimeric conformation during the binding of IL-2. (67) This interaction leads to 
sustained proliferation and survival of T cells. (67, 72, 73) The first step in IL-2 
signalling is the phosphorylation of the intracellular domains of the β-chain 
(CD122) and γ-chain (CD132). (67, 75) Several kinases are phosphorylated and 
implicated in IL-2 induced signalling, which subsequently leads to gene expression 
and multi-effector function. The implicated signalling proteins are Syc, Src and 
STAT. (67, 76) Syk and Src are withheld from CD122. (67) STAT is activated by 
the CD132 intracellular domain. (67, 77, 78)  
The strong IL-2 dependence of T cells (CD4+) after activation, which includes a 
high affinity binding, let us to speculate whether it would be possible to detect such 
T cells by IL-2 decorated VLP. For that purpose we fused the IL-2 gene to the GPI-
anchor of CD16b and we generated fluorescent VLP (FS). IL-2::GPI decorated FS 
would allow in this way the detection of activated, proliferating T cells. 
 
 
1.5  Interleukin-2 receptor 
 
The IL-2 receptor consists of three chains, the α-chain (CD25), the β-chain 
(CD122) and the γ-chain (CD132) (67) The β- and γ-chain are constitutively 
expressed on resting lymphocytes. (67) This heterodimeric receptor acts as the 
intermediate receptor, with an affinity of KD=10-9 M. (67) CD25 has an affinity of 
KD=10-8M, and is not expressed in resting T cells. (67, 79) The complete receptor 
corresponds to the high affinity receptor with KD=10-11M, which is expressed on 
activated T cells. (67)  
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1.5.1 The α-chain (CD25) and its promoter 
 
The α-chain (CD25) molecule is a type I transmembrane protein, which contains 
219 extracellular and 13 intracellular aa. (67) CD25 is localized on chromosome 
10p14-15, the receptor is composed of eight exons and seven introns. (67, 80-82) 
The induction of the expression happens quickly after antigen recognition. (67, 83-
86) The promotor region of CD25 is composed of three positive regulatory regions 
(PRR) I-III. PRR I reveals a very complex binding domain, which requires several 
transcription factors. (67) PRR I contains binding regions for NFκB, serum 
responsive factor (SRF) and Sp1. (67) Furthermore, there are two factors binding 
upstream of NFκB also in, NFIL-2RA or UE1. (67, 87, 88) Downstream of PRR I, is 
PRR II localized which binds Elf-1 (Ets family protein) and the high mobility protein 
HMG-I(Y). (67, 89) PRRIII is localized upstream of PRRI and possesses own 
binding domains for Stat5, Elf-1 and GATA-1-like protein. (67) PRRIII and PRRII 
are essential for IL-2 mediated α- chain (CD25) promoter. (67) It is expected, that 
these two promoter regions require functional cooperativity. (67) 
 
1.5.2 The β-chain (CD122) and its promoter  
 
The β-chain (CD122) is also a type I transmembrane consisting of 214 aa in the 
extracellular and 286 aa in the intracellular domain. (67) The β-chain is localized 
on chromosome 22q11.2-12 and is composed of 10 exons and nine introns. (67, 
90, 91) The CD122 is expressed already in resting T cells (67, 79, 92) The 
promoter region of CD122 contains three enhancer-like regions. (67, 93) The first 
like enhancer region binds GABP and the Ets family proteins Ets-1 and the second 
region recruits the Sp1 factor and early gene product Erg-1. (67, 93, 94) The third 
region contains negative regulatory elements (NRE). (67, 93)  
 
1.5.3 The γ-chain (CD132) and its promoter  
 
The γ-chain (CD132) has 232 extracellular aa and 86 intracellular aa and is a type 
I membrane protein, located on the X–chromosome. (67) The gene is organized in 
eight exons and seven introns. (67, 95-97) CD132 is constitutively expressed (67, 
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77, 78) and contains an enhancer binding domain for Ets that mediates the 
activity. (67, 98)  
The diverse affinities of the IL-2 receptor lead us to test the hypothesis, whether it 
would be possible to distinguish these differences by binding of FS decorated with 
IL-2::GPI. This was the reason for the creation of IL-2 receptor-components which 
are GPI-anchored. The components can be tested in different combinations with 
IL-2::GPI FS on transfected HEK-293 cells. Another possibility is the opposite 
situation, by staining of IL-2::GPI decorated HEK-293 with IL-2 receptor chain-
combinations decorating FS. 
 
1.5.4 Consequence of Interleukin-2 receptor chain knock-out  
 
The loss of the interleukin receptor chains leads to severe combined 
immunodeficiency (SCID). Patients suffer from lack of adaptive immune cells, and 
therefore they are not capable to generate neither specific T cell dependent 
antibody responses nor cell-mediated responses. (69, 70)  Furthermore, the 
capability of developing immunological memory is severely compromised. (69, 70) 
A severe form of SCID is the X-lined SCID, which is frequently caused by the loss 
of the common γ-chain (CD132). (69, 70) CD132 is the signal transducing element 
for several interleukins, among them IL-2, IL-4, IL-7, IL-9 and IL-15. (99-107)  
 
 
Affinity  Composition  Kd Cellular distribution  
Low      α-chain (CD25)   10-8M 
Not expressed in  
resting T cells 
Inter- 
mediate 
    β-chain (CD122) and  
     γ-chain (CD132) 
  10-9M 
Resting  
lymphocytes,  
especially NK-cells 
High 
     α-chain (CD25), 
     β-chain (CD122) and 
     γ-chain (CD132) IL-2R  
  10-11M Activated lymphocytes 
 
Table 1. The IL-2 receptor chain affinities. (67)  
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A consequence of α-chain mutations or knock-out of CD25 is incomplete T cell 
development. (69, 70) The loss of CD122 leads to increased autoimmunity. (69, 
70) Loss of both chains CD122 and CD132 causes severe immunodeficiency. (69, 
70)  
 
Chains  Extra- 
cellular 
Trans-
membrane 
Intra-
cellular 
Molecular 
weight 
α-chain  
(CD25) 219 aa   19 aa 13 aa     55-60 kDa 
β-chain 
(CD122) 214 aa   25 aa 286 aa ~75 kDa 
γ-chain 
(CD132) 232 aa   29 aa 86 aa ~65 kDa 
 
Table 2. The structure of the original human IL-2 receptor chains with the length of the each 
domain in amino acid (aa) and the corresponding molecular weight. (67, 72, 75, 77)  
 
 
1.6  Interleukin-7 function  
 
Interleukin-7 (IL-7) was initially described as 25 kDa factor having activating 
effects on B cells. (107, 111). Afterwards, it was discovered that it has also an 
activating and proliferation inducing influence on T cells. (99, 112-114) The 
importance of IL-7 for the development of T and B cells was proven by depletion of 
IL-7 or by α-chain (CD127) knock-out of IL-7 receptor in mice. (99, 107, 115) IL-7 
deficient mice, (99, 109, 110) lack T cells, B cells, NK cells, NKT cells, whereas 
CD127 deficient mice show a more severe phenotype (108-110) These 
experiments show the necessity for IL-7 for both T and B cells, demonstrating that 
IL-7 is a critical factor during lymphopoiesis. (107) IL-7 expression was detected in 
primary and secondary lymphatic organs such the thymus, bone marrow, spleen, 
and fetal liver. (107, 116-120)  
Primary producers of IL-7 are fibroblastic reticular cells in lymph nodes in the T-
cell zone (108, 121) The IL-7 receptor binds IL-7, via its heterodimeric 
components, (108, 122) which is composed of the common γ-chain (CD132) and 
the IL-7 α-chain (CD127). (101, 103, 107, 108, 122-124) In general IL-7 provides 
pro-survival and proliferating signals which directly influence T and B cell 
development and homeostasis. (108, 125) IL-7 receptor signalling is linked to the 
Jak-Stat and PI3K-Akt pathways. (108, 126) The consequence of the activation of 
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these pathways by IL-7 results in differentiation, survival and proliferation. (108) 
The IL-7 dependence of T and B cells initiated us to study the IL-7 expression on 
this cell types by our FS decorated with IL-7::GPI.  
 
1.7  The green fluorescent protein 
 
The Green fluorescent protein (GFP) is a naturally existing molecule and 
originates from Aequorea victoria of the Cnidaria Family. (4, 5, 127) Since, the 
cloning (Chalfie et al., 1994) of the wild type (wt) GFP, improved versions of the 
molecule have been engineered. They cover a brighter spectral range, exhibit 
enhanced photostability, have a reduced oligomerization tendency and are pH 
insensitive. (127) The new spectral range of the modified wt GFP contains 
different colors for example, blue (BFP), cyan (CFP) and yellow (YFP) (Heim et al., 
1994; Ormö et al., 1996; Tsien, 1998). (127) 
The molecular structure of GFP (Fig.5), is a 40 Amströng (Å) high and 30 Å broad 
β-barrel architecture. (127) The β-barrel of GFP is composed of 11 β-sheets and 
four α-helices. (127) The emission spectrum of GFP ranges from 500 nm to 525 
nm, this wavelength can be modified by mutation of different regions in the protein. 
(127) Another recently discovered fluorescent protein is mcherry of Discosoma sp. 
(4-6), which was chosen for the creation of a deep red (cherry) emitting light at a 
wavelength of 630 nm to 660 nm and which we applied for FS utilized for double 
staining.  
 
Figure 5. Structure of the green fluorescent molecule (GFP)  
from: Nathan C. Shaner, George H. Patterson and Michael W. Davidson (2007) Journal of Cell 
Science 120, 4247-4260  
 
Calin Manta  Introduction 
25 
1.8  Induction of fluorosome production  
 
The research based on the use of virus-like particles (VLP) as platform to 
immunomodulate the function of T-lymphocytes is well established in our 
laboratory. In this project we aimed at engineering a novel staining tool, based on 
the VLP system platform i.e. fluorosomes (FS). This newly engineered staining 
tool, should allow identification of target cells, expressing receptors or interleukins 
(Fig.6). 
 
 
Figure 6. Production scheme of fluorosomes (FS) in MA::GFP stable HEK-293 cells. 
 
The induction of FS budding is dependent on three components (Fig.7). The first 
component is the original gag/pol (OGP) from MoMLV. The gag/pol (OGP) leads 
to induction of VLP. (1, 2) The second component is the MA::GFP, which is 
composed of the GFP fused to the matrix protein (MA) p15 from MoMLV. The third 
component can be the interleukins or interleukin receptor-components, which are 
coupled through a glycine-linker to the GPI-anchor of CD16b. FS were variably 
decorated with the following constructs: IL-2::GPI, IL-2::GPI receptor-components 
(CD25::GPI,CD122-GPI and CD132::GPI) and IL-7::GPI. Constructs were chosen 
because of technical reasons but also because of their involvement in important 
immunologic processes. Current limitations of our system are the types of 
Calin Manta  Introduction 
26 
transmembrane protein classes which allow only the use of type I membrane 
proteins. Both, the MA and the CD16b are molecules, which are targeted into the 
lipid rafts. The MA molecule attaches to the inner leaflet, the CD16b molecule to 
the outer leaflet of the plasma membrane. 
 
 
 
Figure 7. Raft targeted constructs MA::GPF and GPI- anchored IL or IL-receptor. 
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2 Materials and Methods  
 
 
2.1  Expression constructs  
 
The human IL-2 specific cDNA sequence was amplified with primers IL-2 for 5´- 
CGCGGGAAGCTTGCCACCATGTACAGGATG-CAACTCCTG-3´, IL-2 rev 5´- 
CCCGCGGCTAGCGCCGCCGCCAGTCAGTGTTGAGATGATGC-3` from clone 
pTCGF-11 (ATCC #39673, American Type Culture Collection, Manassas, VA), 
derived from PHA activated peripheral blood cells. 
The 5´- ends of the cytokine cDNA were optimized for translation initiation by 
inserting GCC ACC in front of ATG. Hind III and Nhe I restriction sites were 
inserted. The naturally occurring stop codon was deleted by exclusion via PCR. 
Restriction with the corresponding enzymes allowed fusion of the fragment with 
the GPI-anchor acceptor sequence of CD16b. The original MoMLV gag/pol (OGP) 
was expressed using the mammalian expression vector pMD.gag/pol kindly 
provided by Dr.R. Mulligan, Boston, MA. The human CD16b served as negative 
control in the experiments.  
 
Primer  Sequence               RE sites 
GFP  for 5'-CCCGCGGCTAGCGTGAGCAAGGGCGAGGAG-3'             Nhe I 
GFP  rev 5'-GCGCCCGCGGCCGCTTTACTTGTACAGCTCGTCCATG-3'            Not I 
IL-2   for 5'-CGCGGGAAGCTTGCCACCATGTACAGGATG-CAACTCCTG-3'           Hind III 
IL-2  rev 5'-CCCGCGGCTAGCGCCGCCGCCAGTCAGTGTTGAGATGATGC-3'           Nhe I 
IL-2Rα for 5'-CGCGGGAAGCTTGCCACCATGGATTCATACCTGCTGATGTGGGGA-3'          Hind III 
IL-2Rα rev 5'-CCCGCGGCTAGCGCCGCCGCCCTGGTACTCTGTTGTAAATATG-3'           Nhe I 
IL-2Rβ  for 5'-CGCGGGAAGCTTGCCACCATGGCGGCCCCTGCTCTGTC-3'           Hind III 
IL-2Rβ  rev 5'-CCCGCGGCTAGCGCCGCCGCCGGTGTCCTTCCCAAG-3'            Nhe I 
IL-2Rγ  for 5'-CGCGGGAAGCTTGCCACCATGTTGAAGCCATCATTACCATTCACATCCCTC-3'          Hind III 
IL-2Rγ  rev 5'-CCCGCGGCTAGCGCCGCCGCCATTCTCTTTTGAAGTATTGCTCC-3'          Nhe I 
IL-7   for 5'-CGCGGGAAGCTTGCCACCATGTTCCATGTTTCTTTTAGG-3'            Hind III 
IL-7   rev 5'-CCCGCGGCTAGCGCCGCCGCCGTGTTCTTTAGTGCCCATC-3'           Nhe I 
MLV MA  for 5'-CGCGGGAAGCTTGCCACCATGGGCCAGACTGTTACCACT-3'           Hind III 
MLV MA  rev 5'-GCGCCCGCTAGCGGATCGAGGCGGGGTCG-3'             Nhe I 
 
Table 3. List of primers used. The underlined regions indicate the restriction enzyme sites. 
Calin Manta  Materials and Methods 
28 
The MA::GFP was generated by using the p15 matrix protein of MoMLV 
(pMD.gag/pol) as PCR template for the membrane anchor. The primers were 
tailed with Nhe I and Not I restriction sites which allowed insertion into pEAK12 
expression vector. These fragments were digested accordingly and were ligated 
into the pEAK12 expression plasmid.  
 
2.2  Transformation of Escherichia coli MC1061 
 
Plasmids were transformed into Escherichia coli (MC1061) using high efficiency 
heat shock transformation. Competent MC1061, which were mainly used in our 
laboratory for transformations, were stored in aliquots at – 80 °C. The aliquot were 
melted on 4 °C, for each transformation 100 µl from the MC1061 aliquot were 
transferred into a precooled 1,5 ml tube. Ligated plasmid DNA (1 µg) was mixed 
with competent bacteria by gently pipeting up and down. The mixture was 
incubated for 20 minutes at 4 °C. The competent MC1061 were afterwards heat 
shocked by incubating for 5 minutes at 37 °C. The heat shocked and transformed 
MC1061 were spread on selective plates containing 100 µg/ml ampicillin with 
glass beads. The pEAK12 vector carries an ampicillin resistance gene allowing 
selection of plasmid containing bacteria. The selective plates were covered with a 
layer of top agar, which was required for the regeneration of the transformed 
MC1061 and didn`t contain ampicillin. The plate was incubated overnight (16-18 
hours) at 37 °C. Selected colonies were transferred into 4 ml selective LB broth 
with 100 µg/ml ampicillin and further incubated at 37 °C by shaking overnight. 
 
LB medium:  
20 g LB Broth Base (Gibco-BRL) 
0,09 M NaCl 
ddH2O to 1 liter 
 
2.3  Plasmid Mini-preparation  
 
Preparation of DNA was achieved by using DNA purification kit (Nucleospin 
Plasmid) according to manufacturer’s protocol. Single cell cultures, which were 
grown overnight in selective LB broth, were collected in 1,5 ml tubes and 
centrifuged at 11000 g (12.000 rpm) for 30 seconds at room temperature (RT). 
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The supernatant was removed and the cell pellet was resuspended in 250 µl buffer 
A1. The cell lysation step required 250 µl of buffer A2. The tube had to be inverted 
gently for ideal cell lysation. Addition of 300 µl buffer A3 represented the 
neutralization step, which stopped the lysation. The cell lysate was centrifuged for 
10 minutes (11000 g; RT). Insoluble cell components were accumulated to a 
pellet. The clear supernatant, which contains the solved plasmid DNA, was 
completely transferred onto a silica membrane column (Nucleospin Plasmid). The 
column was placed into a 2 ml collecting tube and was centrifuged for 1 minute 
(11000 g; RT). The content of the collecting tube was discarded. In order to wash 
the silica membrane, the column was loaded with 600 µl of washing buffer A4. The 
column containing buffer A4 was once centrifuged for 1 minute (11000 g; RT). The 
column was then dried through centrifugation for 2 minutes, before the DNA was 
eluated. The collecting tube was discarded and column is transferred onto a 1,5 ml 
tube. The eluation was performed by the addition of 50 µl of buffer AE onto the 
column and centrifugation for 1 minute (11000 g; RT). 
 
2.4  Plasmid Maxi-preparation  
 
The plasmid maxi-preparation allowed the extraction of high quantities of plasmid 
DNA. The maxi-preparation required 1 liter of selective LB broth (100 µg/ml 
ampicillin). The transformed bacteria were grown over night at 37 °C. The bacteria 
were first centrifuged and pelleted in a RC-3C Sorvall tube at 10000 g (4200 rpm) 
for 20 minutes at 4 °C. After discarding the supernatant the bacterial pellet was 
resuspended by shaking in 40 ml of precooled solution I (10 mM EDTA, pH8). 80 
ml of solution II (0,1 M NaOH; 1% SDS) were added to the solved pellet. The 
bacteria were lysed by gently swirling of the tubes and by incubating for 2 minutes, 
but not longer than 5 minutes. In a third step was added 40 ml of neutralization 
solution III (5M KOAc (pH4,7)), which stopped the lysation reaction. The resulting 
mixture was shaked vigorously.  
The insoluble debris was removed through centrifugation at 10000 g for 10 
minutes at 4 °C. The soluble supernatant containing the plasmid DNA was 
transferred into 250 ml tubes through a filter cloth. The tubes were filled with 
isopropanol and centrifuged at 10000 g for 15 minutes at 4°C. The supernatant 
was removed and the precipitated DNA pellet was washed once with 70 % ethanol 
and was dried with Kim Wipes (Hakle-Kimberly Clark, Vienna, Austria). The dried 
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pellet was resuspended in 4 ml 10 M EDTA, transferred into Sarstedt 14 ml tubes 
and was mixed with 5,5 g CsCl (Invitrogen, Groning, Netherlands), 100 µl 1 % 
Triton X-100 and 500 µl ethidium bromide (10 mg/ml). The solved mixture was 
centrifuged at 10000 g (10.000 rpm) for 10 minutes at RT with a JS-13.1 rotor. The 
supernatant was filled into Beckman polyallomer quick-seal tubes and sealed for 
ultracentrifugation. The tubes were centrifuged over night at 100000 g (80.000 
rpm) in an Optima TLX ultracentrifuge (Beckman, Polo Alto, CA). The 
ultracentrigtion step leaded to the formation of the CsCl gradient which separated 
the plasmid DNA from chromosomal DNA. The lower band corresponded to the 
plasmid DNA the upper band was the chromosomal DNA. The plasmid DNA band 
should be in an optimal preparation bigger than the chromosomal DNA. After 
ultracentrifugation Beckman tube was cut open, the lower band was collected in a 
2 ml syringe due to aspiration. The plasmid DNA was transferred to a Sarstedt 14 
ml tubes. The next step required 10 ml n-butanol of NaCl saturated to extract the 
ethidium bromide from the plasmid DNA. The upper n-butanol phase was removed 
after 10 minutes holding time. These steps were repeated until coloration of the 
plasmid DNA, changed to a clear solution. The ethidium bromide purified plasmid 
DNA was precipitated with 1 x volume of 1 M ammoniumacetat, mixed well and 
added 2 x volume of 96 % ethanol. The precipitated plasmid DNA was centrifuged 
for 10 minutes at 10000 g with JS-13.1 rotor. The plasmid DNA pellet was once 
washed with 70 % ethanol and dried with cotton swabs. The pellet was 
resuspended in 400 µl TE-buffer (10mM TrisHCl; 1mM EDTA). 
The DNA concentration was determined by optical density (OD) measurements at 
260 nm. In order to control plasmid DNA digestion with corresponding restriction 
enzymes was performed. The digested plasmid was separated in agarose gel 
(Biozym LE agarose) melt in TAE-buffer.  
 
 
50 x TAE stock: 
242 g Tris-Base 
57,1 ml Acetic Acid  
100 ml 0,5 M EDTA 
ddH2O to 1 liter 
 
Calin Manta  Materials and Methods 
31 
2.5  Cell lines  
 
2.5.1 Human embryonic kidney-293 cell line  
 
The human embryonic kidney cell line 293 (HEK-293) was maintained in Iscoves 
Modified Dulbeccos Medium (IMDM) (Sigma Chemicals, St. Louis, MO) plus 10 % 
FCS (Invitrogen, Carlsbad, CA) supplemented with 2 mM L-glutamine, 50 µM 2-
mercaptoethanol and 15 µg/ ml gentamycin sulfate. The HEK-293 cells were 
embryonic kidney epithelial cells transformed by DNA of adenovirus type 5. (66) 
HEK- 293 cells grow as adherent monolayer on the culture dish at 37 °C and 5 % 
CO2. When cell confluence was reached after three days, cells were first washed 
with 1 x PBS. The PBS was removed from the cells and afterwards treated with 
trypsin that detached the cells from the culture dish by proteolysing the adhesion 
molecules of the HEK-293 cells. The treatment with trypsin required 5 minutes 
incubation at 37 °C. The detached cells were washed in 15 ml IMDM for the 
trypsinic digestion stop. The pellet was resuspended and washed once in IMDM 
for removing completely the trypsin. The cells were after this last washing step 
resuspended than counted and replated.  
 
2.5.2 Mouse T cell line HT-2 
 
HT-2 (ATCC, CRL-1841) cells, which are non-adherent and were maintained in 
NCM medium (supplemented). The cells were cultivated in the presence of 100 
U/ml human IL-2 (Peprotech, London, UK). HT-2 cells were subcultured every 
three days at 1 x 105 cells/ml. 
 
NCM medium (supplemented) for primary mouse cells: 
 
RPMI 1640 (PAA laboratories) 
12,5 % FCS (Invitrogen) 
1,25 % Sodium Pyruvate 100 mM (Gibco) 
1,25 % Non-essential amino acids mix 100 x (Gibco) 
1,25 % L-Glutamycin 200 mM (Gibco) 
0,25 % 2-mercatoethanol 50 mM (Sigma) 
Gentamycin sulfate 50 mg/ml (Sigma) 
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3 % HEPES buffer 1 M pH 7,3 (Gibco) 
 
2.6  Primary cells  
 
2.6.1 Peripheral blood mononuclear cells 
 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood 
of healthy adult donors upon informed consent by standard density gradient 
centrifugation with Lymphoprep (Technoclon, Vienna, Austria). The isolation of 
cells was done by Ficoll method preparation. Ficoll also known as polydisperse 
mixtures of dextran, was used for separation of lymphocytes from erythrocytes. 
(128) The human whole blood was piled up carefully on the Ficoll and was 
centrifuged. The cells with high density like erythrocytes were collected at the 
bottom, the PBMC were collected in the upper part of the tube after the 
centrifugation. The PBMC could be recognized in the Ficoll, the respective cells 
looks like white clear coat that could be collected.  
After isolation PBMC were maintained in IMDM or stored in fluid nitrogen with 2 x 
freezing medium. The cells could be activated via beads which resulted in cell 
proliferation. The activation was started 48 hours before using the cells as target in 
the staining experiments. The beads were coated with anti CD3/CD28 antibodies 
and were applied at a ratio of three beads per cell.  
 
2 x freezing medium: IMDM, 20 % FCS and 10 % dimethyl sulfoxide (DMSO).  
 
2.6.2 Peripheral blood mononuclear cells from chronic lymphatic 
leukemia patients 
 
Whole blood samples of CLL patients obtained upon informed consent were anti-
coagulated by EDTA and used in standard whole blood staining using LYSE- 
solution according to the manufacturer´s, recommendations (An der Grub, 
Kaumberg, Austria). 
 
2.7  Ca2PO4-transfection of human embryonic kidney – 293 cells 
 
One day prior to transfection HEK-293 cells were seeded in a 100 mm culture dish 
at a concentration of 3 x 106 cell/10 ml in IMDM containing 2,5 µg/µl plasmocin 
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(InvivoGen) and 1 µg/ml amphothericin (PAA). The medium was replaced at least 
half an hour before transfection with IMDM containing only 1 µg/ml amphothericin. 
Cells were covered with 2 ml transfection mix. The mixture was composed of 870 
µl steril ddH2O, 30 µg DNA, 100 µl CaCl2 (2,5 M) and 1 ml 2 x HBS-buffer. After 
18-24 hours transfection medium was replaced again and transfectant were 
cultured for a further 48 hours with IMDM containing 2,5 µg/µl plasmocin and 1 
µg/ml amphothericin. 
 
2x HBS (HEPES buffer saline): 
 
NaCl (140 mM), 
Na2HPO4 (1,5 mM), 
HEPES (50 mM) 
ddH2O to 1 liter 
 
 
  pEAK12  CD16::GPI 
pEAK12  
CD25::GPI 
pEAK12  
CD122::GPI 
pEAK12  
CD132::GPI 
Intermediate Receptor 10 µg DNA        --- 10 µg DNA 10 µg DNA 
High-Affinity Receptor        --- 10 µg DNA 10 µg DNA 10 µg DNA 
 
Table 5. The DNA mix for HEK293 cell Receptor-components transfection. 
 
  pEAK12  
CD16::GPI 
pEAK12  
CD25::GPI 
pEAK12  
CD122::GPI 
pEAK12  
CD132::GPI 
 pMD gag/pol 
Low-Affinity 
Receptor FS   7,5 µg DNA         ---        --- 7,5 µg DNA  
Intermediate 
Receptor FS  7,5 µg DNA         --- 7,5 µg DNA  7,5 µg DNA  7,5 µg DNA  
High-Affinity 
Receptor FS        --- 7,5 µg DNA  7,5 µg DNA  7,5 µg DNA  7,5 µg DNA  
 
Table 6. The DNA mix for the optimal production of fluorosomes (FS) decorated with receptor-
components. 
 
 pEAK12  
IL-2::GPI 
pEAK12  
IL-7::GPI 
pMD gag/pol 
IL-2::GPI_FS  22,5 µg DNA         --- 7,5 µg DNA 
IL-7::GPI_FS          --- 22,5 µg DNA  7,5 µg DNA 
 
Table 7. The DNA mix for the optimal production of FS decorated with interleukins. 
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2.8 Establishment of stably transfected human embryonic 
kidney-293 cells 
 
Stable transfectants of HEK-293 cells with MA::GFP, GFP or MA::mCherry were 
generated by linearizing pEAK12 with the restrictions enzyme Sfi I (New England 
Biolabs) followed by transfection into HEK-293 cells by the calcium phosphate 
precipitation method. The transfectants were selected with puromycin 1 µg/ml 
(Sigma Chemicals) that was added to the IMDM.  
 
The p_mCherry was cut with Sfi I (New England Biolabs), HEK-293 cells were 
transfected by the modified calcium phosphate precipitation method and selected 
by limiting dilution in 96-well flat bottom plates and maintained in IMDM.  
 
Subcloned transfectants were analyzed by flow cytometry on a FACS Calibur 
(Becton Dickson, Palo Alto, CA) using the Cell Quest software. 
 
2.9  Biochemical analyses  
 
 
2.9.1 Cell lysis for Western blot analyses 
 
The biochemical analyses of transfected cells required cell-lysates which were 
analyzed by Western blotting. The transfected cells were first of all removed from 
the plate with 0,5 mM EDTA/PBS and washed once with PBS. The cell number 
was adjusted to 10 x 107 and lysed with 2 x NP-40 Lysis buffer, for 30 minutes 
strictly on ice (4 °C). The cell-lysates were afterwards centrifuged for 10 minutes at 
80 g (1000 rpm) in an Eppendorf Centrifuge 5424. By this step insoluble cell 
components form a pellet and were removed. The supernatants were used for 
further analyses and 4 x reducing or non-reducing Laemmli sample buffer was 
added. 
 
To perform Western blot with VLP preparations it was required to concentrate the 
secreted VLP in the crude supernatant by ultracentrifugation. The crude 
supernatant was therefore collected and filtered through 0,45 µm Filter (Sarstedt). 
The filtered supernatants were transferred to Beckman Centrifugation Tubes 
(Beckman Instruments, Inc.; Palo Alto, CA; USA) and ultracentrifuged at 100.000 g 
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(28.000 rpm) for 1 hour on Beckman-Optima LE-80 K centrifuge (Beckman) with 
SW-41Ti. The pellet was resuspended in 100 µl 1 x Laemmli sample buffer 
selective in reducing or non-reducing.  
 
2.9.2 Isopycnic sucrose gradient centrifugation 
 
The isopycnic sucrose gradient method separated the cell components due to their 
density, which was important for the detection of lipid raft targeting. The analyzed 
cells were therefore removed from the culture plate with 0,5 mM PBS/EDTA. The 
cell number required for this experiment was 2 x 108. The complete experiment 
was strictly performed on ice (4°C) which means that all materials used have to be 
pre-cooled so as not to solubilize the GPI-anchored proteins from the lipid rafts. 
The cells were after the detaching from the plate washed once with ice old PBS. 
The cell pellet was resusupended in 1 ml ice cold PBS. The resuspended pellet 
was portioned in two 1,5 ml tubes with Triton X-100 2 x Lysing buffer and 
incubated for 30 minutes on ice. The non-ionic detergent Triton X-100 is important 
because ions interact with lipid rafts and the GPI-anchor which result in release of 
the component from each other. (34) The cell lysates were afterwards transferred 
to a glass douncer (Wheaton; Millville NJ; USA) and were dounced for 10 times. 
The dounced lysates were cast in 1,5 ml tube. The insoluble cell components were 
removed by centrifugation for 1 minute at 140 g (2000 rpm) in a Eppendorf 
Centrifuge 5424. The supernatant was collected and mixed due to invertation with 
the same volume of 80 % sucrose in 4,5 ml Cryo Tubes Vials (Nunc) from 10 
minutes on 4 °C. To perform the stacking of the sucrose gradient 1,6 ml of the 40 
% sucrose mixture containing the cell lysate was transferred in polypren Beckman 
Centrifuge Tubes (Beckman Instruments, Inc.; Palo Alto, CA; USA). The next layer 
of 30 % sucrose was stacked to a volume of 1,6 ml over the 40 % mixture. The 
last layer contained 5 % sucrose and had a volume of 0,8 ml. The three different 
layers that can be distinguished by light reflection at their interphases. The 
sucrose gradient was ultracentrifuged at 200.000 g (44.000 rpm) with SW-60Ti 
(Beckman) rotor without acceleration and brake at 4 °C overnight. The 
ultracentrifugation led to separation of the cell components according to their 
density. The gradient is collected in nine fractions 400 µl each. The upper fractions 
number 2 and 3 contained the lipid raft. The lower fractions (6, 7, 8 and 9) 
contained non lipid raft proteins.  
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The fractions were mixed with 4 x Laemmli buffer, reduced or non-reduced. The 
detection was performed by Western blotting.  
 
2 x Triton X-100 Lysis buffer: 
2 % Triton X-100 
0,5 mM EDTA 
25 µg/ml aprotinin 
25 µg/ml leupeptin 
1 mM phenylmethylsulfonylfluorid (PMSF) 
Solubilized in 936 µl MBS (25 mM MES [morpholineethanesulfonic acid],150 mM 
NaCl] 
 
 
2.9.3 Western blot  
 
Samples were boiled at 95 °C for 10 minutes and shortly vortexed for cutting the 
chromosomal DNA. The mix was loaded on a 14-20 % tris polyacryl amid gel 
(PAGE) (Anamed). The gel aperture (Hoefer Pharmacia BioTech, San Francisco 
CA, USA ) was filled with 1 x Gel running buffer, the loaded gel was run at 150 
Volt. The gel was transferred on a pre-cut and methanol activated PVDF 
membrane (PVDF-Immunobilone P, Millipore) or alternatively non methanol 
activated Pure Nitrocellulose Membrane (Transfer-Blot, Transfer Medium, BioRad) 
and four blotting sheets (Filter Paper, Blot adsorbant Filter Paper, BioRad) to a 
Blotting buffer soaked sandwich on the blotting aperture (Hoefer Scientific 
Instruments, San Francisco CA, USA). The blotting time corresponded to 1 hour at 
30 Volt. The blotted PVDF membrane is removed from the blotting sandwich and 
blocked with blocking buffer for 1 hour. After the blocking primary antibody could 
be added and incubated for 2 hours. The membrane was washed 3 times for 5 
minutes with Washing buffer (PBS; 1%Tween). The second antibody which is HRP 
conjugated was added and incubated for 1 hour. The membrane was afterwards 
washed 3 times for 5 minutes in Washing buffer and developed in the darkroom by 
individual exposing on X-ray film (BioMax XAR Film, Scientific Imaging Film, 
Kodak) after incubation for 1 minute in chemoluminiscence substrate (Western 
Lightning, Enhanced Chemiluminescence Substrate, Perkin Elmer). 
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2 x NP-40 Lysis buffer: 
2 % NP-40 
0,5 mM EDTA 
20 µg/ml aprotinin 
20 µg/ml leupeptin 
1 mM phenylmethylsulfonylfluorid (PMSF) 
Solubilized in 940 µl MBS (25 mM MES [morpholineethanesulfonic acid],150 mM 
NaCl] 
 
4 x Laemmli sample buffer: 
4 % sodium dodecyl sulfate (SDS) 
10 % glycerol 
Bromphenol blue (is added to give a dark blue color) 
For reducing Laemmli add 10 % β-mercaptoetanol. 
 
10 x PAGE-buffer: 
0,25 M Tris base 
2,5 M Glycine 
ddH2O to 1 liter 
 
1 x Gel Running buffer: 
1/10 dilution with ddH2O and 5 ml 20% SDS. 
 
1 x Blotting buffer: 
15 % 10x PAGE-buffer  
30 % methanol  
ddH2O to 1 liter 
 
Blocking buffer: 
10 % milk powder  
1 ml Tween20 (BioRad) 
PBS to 1 liter 
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Primary Antibody 
CD59 MEM-43/5 mouse Exbio, Praha, Cech Republic  
CD147 MEM-M6/6 mouse Exbio, Praha, Cech Republic 
IL-2 IL-2.1F10 mouse Dr. Majdic, Inst. Immunol, Vienna Austria  
GFP   rabbit antibodies-online, Aachen, Germany 
CD25  AF2438   mouse  R and D systems, Vienna, Austria 
CD80 mem223 goat Exobio, Praha, Cech Republic 
P30  R187  rat ATCC, Ratitan, NY 
Gag  
Secondary Antibody 
Mouse Ig goat   HRP DAKO, Glostrup, Denmark  
Rat Ig  rabbit   HRP DAKO, Glostrup, Denmark  
Rabbit Ig goat   HRP DAKO, Glostrup, Denmark  
 
Table 8. Primary and secondary immunoblotting antibodies (HRP, horse radish peroxidase) 
 
 
2.10 Detection of the transfectants by bifocal microscopy 
 
Stable transfectants were seeded at density of 4 x 104 cells/cm2 in a PeCon POC-
R cell cultivation chamber and were grown overnight at 37 °C and 5 % CO2. The 
adherent cells were afterwards analyzed by microscopy on an Axiovert 100 M 
confocal microscope using a 63x/1.40 oil immersion objective (Carl Zeiss, 
Göttingen, Germany). 
 
2.11 Flow cytrometric analyses of cells 
 
For the analyses by flow cytometry the cells were removed from the culture dish 
with 0,5 mM ETDA/PBS and once washed with PBS and are centrifuged (500 g 
(1700 rpm); 5 min.) The pellet was resuspended in ice cold (4 °C) FACS buffer 
and cells were ceased to a number of 5 x 106 cells/ml (200.000 cells/50 µl). The 
cell number was measured with a cell counter (Z2 Coulter Counter, Cell and 
Particle counter, Beckman Coulter). 
 
The FS producer cells HEK-293 MA::GFP and HEK-293 GFP were measured in 
FACS, after the determination of the cell number. The negative cell reference was 
used for life gating with propidium iodide. 
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50 µl (200.000 cells) of the read out cells HEK-293, HT-2 or PBMC were added to 
a volume of 20 µl antibodies or 20 µl FS (concentration 1 µg/µl) in 5 ml FACS tube 
(BD Falcon). Cells, which were performed with antibodies, were incubated on ice 
(4 °C) and cells performed with FS were incubated at room temperature. Both 
antibodies and FS required 30 minutes incubation time in the dark. The cells were 
afterwards washed with FACS buffer, centrifuged at 4 °C (500 g; 5 min.) and were 
resuspended in 100 µl FACS buffer. In case of secondary antibody, cell pellet was 
resuspended in 50 µl FACS buffer and incubated with secondary antibody for 30 
minutes. Cells were washed once with FACS buffer after the incubation time. 
 
Primary Antibody 
CD3 S4.1 mouse APC Invitrogen (Caltag), Carlsbad, CA 
CD19 SJ25-C1 mouse APC Invitrogen (Caltag), Carlsbad, CA 
CD99 3B2/TA8 mouse  FITC Caltag Laboratories, Burlingame, CA 
CD59 MEM43 mouse FITC Exobio, Praha, Cech Republic 
IL-2 IL-2.1F10 mouse Dr. Majdic, Inst. Immunol, Vienna Austria  
CD25  2A3  mouse  FITC  BD-Pharmingen, San Diego, CA 
CD122  27302  mouse  FITC  RD, Minneapolis, MN 
CD127  R34.4 mouse  PE  Beckman-Coulter (Immunotech),  
Fullerton, CA 
CD132  TUGh4  mouse  PE  BD-Pharmingen, San Diego, CA 
Combitest GCT_202 FITC  An der Grub (ADG), Kaumberg, Austria 
neg. con.  /PE 
CIAP VIAP  mouse  FITC  Dr. Majdic, Inst. Immunol, Vienna, Austria 
IL-2  MQ1-17H12  rat  PE  BD-Pharmingen, San Diego, CA 
Secondary Antibody 
Mouse Ig goat  OG  Invitrogen (Molecular Probes),  
Eugene, OR 
 
Table 9. The used primary and secondary antibodies in flow cytometry. (PE, phycoerythrin; FITC, 
fluorescein isothiocyanate; APC, allo phycocyanine; OG, Oregon green) 
 
 
Whole blood staining required also cell concentration determination with Zap-
Oglobin which lysed the erythrocytes. The cell number was adjusted with FACS 
buffer and cells were incubated with 20 µl antibody or FS for 30 minutes at room 
temperature (RT) in 5 ml FACS tubes. Cells were treated with 100 µl LYSE 
solution ( An der Grub (ADG), Kaumberg, Austria) and incubated for 10 minutes. 
Afterwards 5 ml FACS tube was filled with ddH2O, once incubated for 10 minutes 
and centrifuged (500 g; 5 min). 
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FACS buffer: 0,5 % bovo serum albumin (BSA); 0,05 % (10 %) Acid N3 
 
 
2.12 Phosphatidylinositol phospholipase C release  
 
The Phosphatidylinositol phospholipase C (PI-PLC) from Bacillus thuringiensis 
releases GPI-anchored proteins treated cells were afterwards analyzed by flow 
cytometry. For this purpose cells were removed from culture plate due to 0,5 mM 
ETDA/PBS and once washed with PBS and centrifuged (500 g (1700 rpm); 5 
min.). The pellet was resuspended in ice cold (4 °C) PBS with the cell number of 
500.000/50 µl. 50 µl of adjusted cells were treated with PI-PLC and 50 µl are left 
untreated as control. PI-PLC treated cells received 0,1 U/ml PI-PLC. Treated and 
untreated cells were kept for 2 hours at 37 °C to reach an optimal result, it is 
indicated to shake the samples occasionally. PI-PLC became unspecific after 2 
hours, therefore it was important not to exceed the incubation time. The treated 
cells should be washed once with PBS (500 g; 5 min.) to remove the PI-PLC from 
the sample. The pellet was resuspended in ice cold (4 °C) FACS buffer to a cell 
number of 500.000/50 µl, add to 20 µl of primary antibody in 5 ml FACS tubes and 
incubated for 30 minutes on ice (4 °C) in the dark. The washing step was 
performed: By filling of the 5 ml FACS tube with FACS buffer, centrifugation (500 
g; 5 min.) and pellet resuspention in 100 µl FACS buffer. 
 
2.13 Purification and application of fluorosomes 
 
The crude supernatant of stable MA::GFP cells that were transfected could be 
harvested after 72 hours and cleared of cellular debris by filtration through 0.45 µm 
(Millipore, Billerica, MA). The standard quantity used in our laboratory to obtain 
high particle concentration is 60 ml supernatant (10 ml supernatant per culture 
dish). The filtrated fluorosomes (FS) were concentrated due to ultracentrifugation 
in a Beckman-Optima LE-80K centrifuge (Beckman) the used rotor was the 
SW41Ti, at 100.000 g (28.000 rpm) for 1 hour and washed once in 10 ml PBS per 
culture dish. The supernatant was once centrifuged for 1 hour the FS pellet was 
resuspended in 120 µl FACS buffer. The protein concentration was measured by a 
standard protein assay (Micro BCA, Pierce). The standard protein assay uses a 
bovine serum albumin (BSA) standard curve to determine the protein 
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concentration of the sample. The BSA concentrations used for the standard curve 
are 200 µg/ml, 40 µg/ml, 20 µg/ml, 10 µg/ml, 5 µg/ml, 2,5 µg/ml, 1 µg/ml and 0 
µg/ml (blank). The FS were diluted 1/100 and the sample was distributed in 96 well 
and was measured after 2 hours incubation at 37°C. The measurement was 
performed by a Photometer (ThermoMax Kinetic Microplate Reader, MWG-
Biotech) at 595 nm. The BSA standard curve led to a raw value for the FS protein 
concentration. The raw value was multiplied with 100 x which corresponded to the 
dilution factor. The multiplied value represented the stock solution of the FS after 
ultracentrifugation. The protein concentration factor from 60 ml crude supernatant 
to 120 µl ultracentrifuged stock was 500 x. The stock solution was applied at a 
concentration of 1 mg/ml in a volume 70 µl, which contained the cells and FS.  
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3 Results 
 
3.1  MA::GFP is targeted to the producer cell plasma membrane 
 
3.1.1 Detection by bifocal microscopy 
 
In a first step we compared MA::GFP and GFP transfected HEK-293 cells for their 
fluorescence characteristics. Our principle hypothesis was that the influence of the 
matrix protein (MA) fused to GFP would enhance targeting of the construct into 
lipid rafts. The signal emitted by MA::GFP cells should be exclusively detected in a 
high amount in the plasma membrane, which should in the additional presence of 
a budding trigger result in the secretion of high intense fluorosomes (FS). For 
GFP, which is a cytosolic protein, we would expect an even distribution throughout 
the cell and no targeting to the cell membrane. In a first step we generated stable 
transfectants for GFP and MA::GFP, which would allow us to produce FS under 
controlled conditions independently of transfection efficiencies. 
 
Figure 8. Microscopy picture of (A) MA::GFP and (B) GFP transfected HEK-293. Pictures (inset: 
high magnification) show characteristic morphology and fluorescence pattern. 
 
The establishment of the stable HEK-293 MA::GFP and HEK-293 GFP, was 
achieved by linearization of pEAK12 vector containing the genes for MA::GFP and 
GFP. The vector was linearized with the Sfi I restriction enzyme. Successful 
integration of the construct was selected by culture in medium containing to 
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puromycin. In a first experiment GFP and MA::GFP expression levels and 
subcellular distribution were analyzed by confocal microscopy.  
Figure 8A demonstrates the clear cut-association of MA::GFP with the membrane 
and gives already a first hint about fluorescence intensities. The soluble GFP 
expressed in the HEK-293 GFP stable transfectant (Fig. 8B) is distributed 
throughout the whole cell and is not concentrated in a special cell organelle or in 
the membrane.  
 
3.1.2 Flow cytometric analyses of the producer fluorosomes cell 
 
While targeting of the fluorescent dye is necessary for efficient fluorosomes (FS) 
production expression intensity also plays an important role. To clarify whether 
MA::GFP and GFP show fluorescence intensity in a comparable range we 
measured stable HEK-293 MA::GFP and stable HEK-293 GFP cells by flow 
cytometry to define mean fluorescent intensity (MFI) values of the corresponding 
transfectants. 
 
 
Figure 9. Flow cytometric measurement of the GFP expression intensity in fluorosomes (FS) 
producer cells. Overlay histograms of stable transfectant HEK-293 producer cells with (A) MA::GFP 
and (B) GFP (solid lines). The negative controls used for the overlay are wt HEK-293 cells (dotted 
lines). The values correspond to the reached mean fluorescence intensity (MFI) of MA::GFP and 
GFP transfectants respectively. 
 
The flow cytometric results (Fig. 9) reveal that expression of MA::GFP in stable 
transfectants is in fact approximately 3-fold lower compared to intensity of GFP 
stable transfectants. The essential statement gained by these results, is that 
MA::GFP is preferentially targeted into the cell membrane and is strongly 
expressed in stable transfectants.  
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3.1.3 GFP fused to the matrix protein MA (MA::GFP) and Interleukin-
2::GPI are targeted into lipid rafts  
 
In order to take a more detailed look at lipid raft targeting we performed analyses 
of cell lysates after isopycnic sucrose gradient centrifugation.  
For that purpose HEK-293 cells were transfected with IL-2::GPI, MoMLV gag/pol 
(OGP), MA::GFP or GFP and lysed. The lysis was strictly done at 4°C in Triton X-
100. The method is based on separation of cell components via a sucrose gradient 
according to their density. Lipid rafts have a low density and are thereby separated 
from transmembrane components that have a high density. The lipid raft 
components can be found mainly in the second and the third fraction, while high 
density components especially transmembrane proteins are localized in the lower 
fractions 6, 7, 8 and 9.  
 
Figure 10. Isopycnic sucrose gradient of HEK-293 transfected with IL-2::GPI, MoMLV gag/pol 
(OGP) (p30Gag), MA::GFP and GFP. The blots in (A) correspond to cells transfected with hIL2, 
MoMLV gag/pol (OGP) (p30Gag) and MA::GFP, the blots in (B) correspond to lysates of 
transfectants probed with the indicated ingredients: hCD59 (pos. control), hCD147 (neg. control) 
and GFP (neg. control to MA::GFP).  
 
The results of the sucrose gradients (Fig. 10) analyzed by Western blotting, 
confirm our expectations. All constructs used in the fluorosomes (FS) (IL-2::GPI, 
gag/pol (OGP), MA::GFP) are targeted to the lipid raft. The gradients demonstrate 
in all three cases strong signals in the second and third fraction. For IL-2::GPI 
(Fig.10A) we observed the clearest result with a strong signal in the second 
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fraction and only low signal in the fractions 6-9. The signal (Fig. 10A) of the capsid 
protein (gag/pol (OGP)) and MA::GFP are not clear-cut (Fig. 10B). Both gag/pol 
OGP) and MA::GFP show not only signals in the second and third fraction but also 
in the non lipid rafts fractions 6-9. 
The used controls are CD59 and CD147. The CD59 (Fig. 10B) is a constitutively 
GPI-anchored molecule and used as positive control for sucrose gradients but also 
for PI-PLC releases. The CD147 molecule is a constitutively transmembrane 
protein, which is excluded from lipid rafts. The comparison of gag/pol (OGP) and 
MA::GFP with the negative controls CD147 and GFP, reveal for these two 
constructs also some signal in the upper fractions (2 and 3), while this was not the 
case for the negative controls. The negative controls, especially the GFP (Fig. 
10B) transfectant don’t show any signal in the upper fractions.  
In conclusion, these analyses reveal that all three components are targeted well to 
lipid rafts at significant percentages and are therefore suited for the production of 
FS. 
 
3.2 Comparison of fluorosomes from MA::GFP and GFP producer  
cells 
 
3.2.1 MA::GFP fluorosomes show significantly stronger fluorescence 
intensity than GFP fluorosomes 
 
The experiments described above show that MA::GFP is stronger targeted to lipid 
rafts and strongly expressed in stably transfected cells. The following experiments 
focus on the main question of our work, staining of target cells expressing a 
respective receptor with fluorosomes (FS). 
As a proof of principle, we decided to compare the fluorescence intensity emitted 
from both particles, the MA::GFP+ VLP (MA::GFP FS) and the GFP+ VLP (GFP 
FS), on the HT-2 cell line. HT-2 is a mouse T cell line constitutively expressing the 
mIL-2 receptor on the cell surface, which also has the property to bind human IL-2.  
For that purpose, FS from the above mentioned MA::GFP and GFP stable 
transfectants were transiently transfected with human IL-2::GPI and gag/pol (OGP) 
of MoMLV to induce particle budding. These producer cells were cultured for three 
days, the secreted FS were purified from supernatants and were used for staining 
of the HT-2 cells as described in Material and Methods. FS were used in the same 
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way as antibodies, which means that the read out cells were incubated for 30 
minutes at room temperature with IL-2::GPI decorated FS (IL-2::GPI FS), 
afterwards washed with FACS-buffer, centrifuged and analyzed by flow cytometry. 
Furthermore, in parallel experiments we tried to block the mIL2-receptor by the 
addition of soluble IL-2. The aim of these inhibition experiments is to show the 
specificity of the binding reactions. For that purpose the HT-2 cells were pre-
incubated for 30 minutes on ice with 5000 U soluble IL-2 and afterwards stained 
with human IL-2::GPI FS as described above.  
Figure 11 (A) and (B) depict the staining with GFP FS and MA::GFP FS decorated 
with IL-2::GPI on the HT-2 readout cells. The staining results obtained with IL-
2::GPI MA::GFP FS (Fig.11B) reached a geometric mean fluorescence intensity 
(geo MFI) of 467 compared to 26 for IL-2::GPI GPF FS. Thus IL-2::GPI MA::GFP 
FS revealed an approximately 20-fold stronger staining intensity compared to IL-
2::GPI GFP FS. These results confirmed our hypothesis that the preferential 
targeting of MA::GFP into MA::GFP FS, results in high staining efficiency. In 
contrast, IL-2::GPI GFP FS, showed low staining intensities when using equal 
protein quantities and are thus not suitable for use in FS.  
The results of the soluble IL-2 inhibition experiment (Fig. 11D), which represent an 
average of three independent experiments, reveal the specificity of binding 
reaction to the IL-2 receptor, of HT-2 cells. The first diagram of Figure 11D shows 
a standard staining with IL-2::GPI MA::GFP FS. This staining is our positive 
reference for the inhibition, which corresponds to 100% cell binding. The second 
diagram of Figure 11D corresponds to the inhibition experiment with soluble IL-2 
and the third diagram shows the control-transfected cells, which is our negative 
control. As it can be recognized in the diagram one and two (Fig. 11D), soluble IL-
2 blocks the IL-2 receptor of the pre-incubated HT-2 target cells. The consequence 
is the binding inhibition of IL-2 MA::GFP FS to the IL-2 receptor of HT-2 cells in a 
statistical significant manner. The soluble IL-2 inhibition experiment demonstrates 
the high binding specificity of the IL-2::GPI MA::GFP FS, while nearly 100% of the 
stained HT-2 cells lose their signal after incubation with soluble IL-2. Comparing 
the low reached binding percentage for both control-transfected FS and IL-2::GPI 
MA::GFP FS in the inhibition experiment determine a very high significance 
because of the less difference between both values. 
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The conclusion of the inhibition experiment with soluble IL-2 after pre-incubation of 
HT-2 cells is the confirmation of the specificity of the binding reactions which is 
completely inhibited subsequent binding of IL-2::GPI MA::GFP FS. 
 
 
 
Figure 11. Overlay histograms of HT-2 cells (2 x 105) incubated with 30 µg IL-2::GPI MA::GFP+ 
VLP (FS) or control MA::GFP+ VLP (FS) (B), IL-2::GPI GFP+ VLP or control GFP+ VLP (FS) (A), 
and anti-CD25 mAb or control mAb (C) are shown. Specific fluorescence (solid lines) is compared 
to the respective control (dotted lines). Numbers indicate geo MFI values of specific reagents.  
Exogenous IL-2 inhibits binding of IL-2::GPI MA::GFP+ VLP (FS) (D). Native HT- 2 cells (2 x 105) or 
HT-2 cells pre-incubated with recombinant soluble human IL-2 (5 x 103 U) for 30 min. on ice were 
incubated with IL-2::GPI decorated MA::GFP+ VLP (FS) and analyzed by flow cytometry. Results 
show binding of IL-2::GPI decorated MA::GFP+ VLP (FS) to IL-2 pre-incubated relative to native 
HT-2 cells (mean + SD).  
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3.2.2 Western blot analyses of MA::GFP and GFP producer cells and 
their corresponding fluorosomes 
 
Furthermore, we wanted to investigate the reason for the different staining 
intensities shown in Figure 11. Our hypothesis is that GFP fluorosomes (FS) 
contain decreased concentration of soluble GFP which is spread in the cytosol and 
is transfused into the particles during the secretion process from GFP stable 
transfectant. The reduced fluorescence intensity of VLP bearing soluble GFP 
compared to MA::GFP was confirmed by GFP-specific immunoblotting.  
For that purpose, HEK-293 producer cells stably transfected with MA::GFP or GFP 
were transiently transfected with gag/pol (OGP) for the VLP induction and 
afterwards cultured for three days. Afterwards, cell lysates were prepared and the 
FS were collected from the supernatant and purified. These cell lysates and the 
purified FS were specifically immunoblotted for GFP and p30 Gag which was used 
as loading control. 
 
Figure 12. Differential targeting of MA::GFP and GFP to VLP (FS). HEK 293 cells were transfected 
with the indicated expression plasmids or control plasmid and cell lysates (cells) and corresponding 
VLP preparations were analyzed by SDS-PAGE under reducing conditions followed by 
immunoblotting (IB) with a GFP-specific goat antiserum or the p30 Gag (gag/pol (OGP)) specific 
mAb R187, respectively. Bound antibodies were detected by a HRP-conjugated secondary 
reagents and a luminol-based detection system. 
 
The GFP specific immunoblotting (Fig. 12) for both MA::GFP and GFP producer 
cells reveal approximately the same signal intensity when using a comparable cell 
number. As expected the specific band for MA::GFP shows high molecular weight 
(~52 kDa) compared to GFP (~30 kDa), which is due to the fusion of the GFP 
gene to matrix protein (MA) more heavy. The control transfected cells don’t show 
any signal. However, immunoblotting of the purified supernatant reveal different 
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signal intensities for GFP. In the MA::GFP FS probe, a strong bound can be found, 
while in the GFP FS only a weak residual GFP signal is detectable. As expected 
no signal is found in the control vesicle. Especially this experiment confirms the 
hypothesis of inefficient GFP targeting into GFP FS. 
 
3.2.3 Dose-dependent quantification of binding of Interleukin-2 
decorated MA::GFP and GFP fluorosomes to HT-2 cells  
 
In the following experiment we addressed the question of dose dependent binding 
of fluorosomes (FS) to determine the ED50 for HT-2 binding. Therefore we tried 
both to determine the FS concentration needed to predict positively stained cells 
and staining intensities measured by the geometric mean fluorescence intensity 
(geo MFI) of the target cells. For that purpose, we analyzed the binding of titrated 
IL-2 decorated MA::GFP+ VLP (IL-2::GPI MA::GFP FS), compared to IL-2 
decorated GFP+ VLP (IL-2::GPI GFP FS) by flow cytometry to HT-2 cells. The 
control-transfected CD16b MA::GFP+ VLP (MA::GFP FS) and GFP+ VLP (GFP 
FS) were also titrated as negative control, giving a hint about the background 
binding. 
Figure 13A shows the FS titration of the IL-2::GPI MA::GFP FS which leads to a 
sigmoid curve with a saturating binding at 4 µg FS (>95% of HT-2 positive). We 
obtained a half maximal binding (ED50) with 1 µg IL-2::GPI MA::GFP FS. The ED50 
corresponds to 50 % of positive stained target cells reached with 1 µg using IL-
2::GPI MA::GFP FS. In contrast the titration with IL-2::GPI GFP FS reaches the 
same value with almost 15 µg. In marked contrast, IL-2::GPI GFP FS produced 
significantly weaker signals, with only 62 % positive cells at the maximal 
concentration. The staining with both CD16b control-transfected FS reveals also 
that high particles quantities result in minimal background staining. The result of 
this titration experiment shows the particle quantities needed to reach a saturation 
point and a half maximal binding of IL-2::GPI MA::GFP FS and it underlines the 
quantitative difference of both FS preparations in staining of HT-2 cells. 
Figure 13B shows the correlation between the quantity of FS used for staining and 
the corresponding geo MFI of the stained HT-2 cells. The staining intensity 
reached a geo MFI of 467 using 30 µg of IL-2::GPI MA::GFP FS, compared to 26 
for IL-2::GPI GFP FS. Both, CD16b control–transfected FS (MA::GFP and GFP) 
show very decreased geo MFI < 8. The result of this experiment shows the 
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application of the FS as they give the quantitative evidence for the high staining 
efficiency of IL-2::GPI MA::GFP FS. Furthermore they allow to determine the 
optimal protein concentration for staining. 
 
 
Figure 13. Binding of IL-2 decorated FS to IL-2 receptor positive HT-2 cells. Dose dependent 
binding. Two-fold dilutions of similar amounts of purified IL-2::GPI MA::GFP+ VLP (FS) (closed 
squares), control MA::GFP+ VLP (FS) (open squares), IL-2::GPI GFP+ VLP (FS) (closed circles) 
and control GFP+ VLP (FS) (open circles) were incubated with HT-2 cells (starting with 30 µg VLP / 
2 x 105 HT-2 cells) at room temperature for 30 min, washed twice and analyzed by flow cytometry. 
(A) Percent positive cells and (B) geometric mean fluorescence intensities (geo MFI) obtained are 
plotted against the VLP concentrations applied. Native HT-2 cells revealed a geo MFI of 5 (< 2 % 
positive cells). ED50 is shown as dotted line. Statistical significance was calculated by the two-
tailed Mann Whitney U-test; * p < 0.05; ** p < 0.01; *** p < 0.001 
 
 
Calin Manta  Results 
51 
3.3  Evaluation of fluorosome stability 
 
3.3.1 Fluorosome stability over time 
 
We wanted to know more about the staining activity of our fluorosomes (FS) upon 
storage for different periods of time. This investigation of the FS stability was also 
performed on HT-2. The FS were tested for time and temperature stability. The 
stability criterion of the FS is very important. For all experiments described so far, 
freshly isolated and purified FS were used. However, in order to be able to apply 
the FS routinely we had to determine whether FS remain stable over prolong 
stronger times. For diagnostically application it is necessary to know, how to store 
the particle and how long.  
As a proof of principle for the stability of IL-2::GPI MA::GFP FS upon prolonged 
storage at 4°C, five independent IL-2::GPI MA::GFP FS preparations were tested 
over the time length of four weeks. These FS preparations were once isolated, 
purified and used for the staining experiment. The remaining preparation was 
stored at 4°C and used to evaluate staining ability on HT-2 cells every week. 
 
Sample 
GeoMean 
  (day 0) 
GeoMean 
  (day 7) 
GeoMean 
 (day 14) 
GeoMean 
 (day 21) 
GeoMean 
 (day 28) 
GeoMean   
(Δ0−28 in %)a 
VLP #1 115 119 124 122 68 40.9 
VLP #2 108 108 111 112 62 42.6 
VLP #3 135 148 146 121 85 37.0 
VLP #4 112 110 116 120 63 43.7 
VLP #5 98 98 92 72 44 55.1 
Mean     113,6    116,6    117,8    107,4    64,4 43.9 
SD    ±13.6    ±19.1    ± 19.7    ±21.3    ±14.6 6.8 
 
Table 10. Stability of IL-2 decorated fluorosomes upon prolonged storage at 4°C. Five particles 
samples measured independently of each other. First geometric mean fluorescence intensity (geo 
MFI) (day 0) is the reference value, following values are obtained by measurements every 7 days. 
The Mean corresponds to the average and SD is the corresponding standard deviation. Geo MFI a 
% variation compared to initial value (day 0). 
 
The values (Tab.10) reveal that particle staining intensities stay unchanged for 
three weeks. After that time, FS rapidly lose staining capacity. The reason for this 
observation cloud be the complexity of our tool which is a whole virus containing a 
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broad range of different molecules such as capsid proteins, the decoration 
proteins and lipids, which must all stay intact in their composition and distribution. 
However, despite of this complexity, FS remain stable for three weeks which 
allows to perform several staining experiments from one preparation 
 
3.3.2 Stability of fluorosomes upon freezing and re-thawing 
 
In a next step we were interested to estimate the physical stability of fluorosomes 
(FS).  
For that purpose five independent IL-2::GPI MA::GFP FS preparations were 
purified by ultracentrifugation and were resuspended in FACS buffer frozen at -
80°C and re-thawed after 24 hours before their binding to HT-2 cells was 
determined and compared to freshly prepared FS. The FS showed remarkable 
stability upon freezing at – 80 °C and subsequent re-thawing since only a 8.8 ± 3.0 
% loss of staining intensity with no loss in the number of positively identified cell 
numbers was apparent (Table 11).  
In marked contrast, FS lost their ability to stain HT-2 cells within days when stored 
at room temperature or 37°C (not shown). 
 
 
  Sample  GeoMean 
(RT) 
 GeoMean 
(-80°C) 
 GeoMean 
(Δ in %)a 
 % positive 
(RT) 
% positive 
   (-80°C) 
% positive 
   (Δ in %)b 
  VLP #1 69 61 8 100 99,0 1,0 
  VLP #2 69 65 4 100 99,7 0,3 
  VLP #3 72 62 10 100 99,8 0,2 
  VLP #4 66 54 12 100 99,8 0,2 
  VLP #5 68 58 10 100 99,8 0,2 
  Mean 68,8 60 8,8 100 99,6 0,4 
   SD ± 2,2  ±4,2 ± 3,0 ± 0 ± 0,4 ± 0,4 
 
Table 11. Stability of IL-2 decorated fluorosomes (FS) upon freezing and re-thawing. a  Reduction 
of geometric mean fluorescence intensities (geoMean) or b positively stained IL2 receptor 
expressing HT-2 cells upon freezing and re-thawing of fluorosomes. Data show mean values ± 
standard deviations from five independently performed experiments. GeoMeans of native HT-2 
cells and HT-2 cells incubated with similar amounts of control FS were 2.6 ± 0.4 and 4.6 ± 0.5, 
respectively.  
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3.4  Determination of binding affinities of the fluorosomes 
 
The IL-2 receptor is composed of three chains, the α-chain (CD25), β-chain 
(CD122), and γ-chain (CD132). (67) The IL-2 receptor changes the affinity 
depending on the receptor components that are expressed, the low-affinity 
receptor (10-8M) is only composed of the α-chain, the intermediate-affinity receptor 
(10-9M) is composed of β- and γ-chain and the high-affinity receptor is composed 
of all three chains. (67, 71, 77, 79, 129-131) While the intermediate-affinity 
receptor is constitutively expressed on resting T cells the high-affinity receptor 
expression is induced upon T cell activation. (67, 71, 132) Because of this affinity 
differences, we asked if it would be possible to detect this binding differences with 
the fluorosomes (FS) via flow cytometry. The read out cells for these experiments 
were HEK-293 cells. Therefore this cancer cell line was transiently transfected with 
the decoration constructs. The IL-2 receptor variants were tested by two different 
ways: (i) by the transfection of HEK-293 cells with receptor components followed 
by staining with IL-2::GPI MA::GFP FS and (ii) by the opposite situation: IL-2::GPI 
transfected HEK-293 cells stained with IL-2 receptor decorated FS. 
 
 
3.4.1 Molecular details of the applied GPI-anchored Interleukin 
receptor-components  
 
 
The GPI-anchor CD16b was fused to the extracellular (Tab.2) domains of IL-2 
receptor chains. 
 
 
 
 
 
 
Table 12. The IL-2 receptor chains fused to the GPI-anchor of CD16b with a length of 138bp. (The 
length and weight of the constructs include also the GPI-anchor). 
 
 
 
       Chains construct length molecular weight 
α-chain (CD25)          858 bp     50-60 kDa 
β-chain (CD122)          857 bp     70-80 kDa 
γ-chain (CD132)          899 bp     60-70 kDa 
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3.4.2 Expression control of GPI-anchored α-chain (CD25) 
 
In a next step we wanted to know if the GPI-anchored α-chain (CD25) of the IL-2 
receptor is expressed on HEK-293 cells and their secreted VLP. 
 
Figure 14. Immunoblot of the α-chain (CD25) on transfected HEK-293 cells and VLP. (A) are cell 
lysates and the corresponding VLP from CD25 transfected and control transfected HEK-293, the 
positive control are activated human PBMC. The isopycnic sucrose gradient (B) of CD25 
transfected HEK-293, the positive control CD59 and the negative control CD80.  
 
 
To investigate the expression of α-chain (CD25), HEK-293 cells were Ca2PO4-
transfected with the construct and with gag/pol (OGP) for VLP budding. The cells 
were lysed and the corresponding VLP were purified, three days after transfection 
with α-chain (CD25). Furthermore, we looked due to isopycnic sucrose gradient 
centrifugation for lipid rafts targeting of the construct.  
The results of the Western blot (Fig.14A) show the clear expression of the α-chain 
(CD25) on the transfected HEK-293 cells and also on their secreted VLP, on the 
other hand mock control-transfected cells and VLP don`t show any signal. The 
positive control are coated beads (anti CD3/CD28) activated human PBMC. The 
signal of the α-chain (CD25) in the immunoblot is strong and at the expected high 
of ~ 60 kDa. The VLP show also clear targeting of the construct. Moreover, the 
results (Fig. 14B) of the sucrose gradient centrifugation reveal a clear-cut lipid raft 
targeting of the α-chain (CD25), which is mainly contained in fraction two and 
three. The positive control is CD59, which is lipid raft targeted. The negative 
Calin Manta  Results 
55 
control is the CD80 which is clearly not lipid raft targeted and contained in fraction 
6-9. The Western blots of Figure 14 demonstrate the expression of the GPI-
anchored α-chain (CD25). in transfected HEK-293, in the VLP and show also 
significant lipid raft targeting. 
 
3.4.3 Phosphatidylinositol phospholipase C releases the GPI-anchor 
from Interleukin-2 receptor-components 
 
 
Figure 15. PI-PLC release of human IL-2 receptor GPI-anchored chains. The three upper 
histograms correspond to the human IL-2 receptor chains. CD59 is a GPI-anchored receptor, 
corresponds to the positive control, CD99 is a transmembrane receptor used as negative control. 
The percentage values correspond to the release of the receptors. 
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While GPI-anchoring of our constructs is essential for the targeting to the lipid rafts 
and such the budding into the VLP we investigated the anchoring by 
phosphatidylinositol phospholipase C (PI-PLC) release and analyses by flow 
cytometry. GPI-anchored constructs treated with PI-PLC are released and can as 
result no longer be detected by flow cytometry.  
In order to check the constructs release after the PI-PLC treatment HEK-293 cells 
were Ca2PO4-transfected with the α-chain (CD25), the β-chain (CD122) and the γ-
chain (CD132). Three days after the transfection HEK-293 cells were detached 
from the culture plate and afterwards separated in two groups. The first group was 
treated with PI-PLC the second group was left untreated and such used as 
positive control. The treatment with PI-PLC requires an incubation time of 2 hours 
at 37°C. 
Figure 15 shows the flow cytometric analyses of the PI-PLC release of the three 
constructs (α-, β-, γ-chain), their untreated positive control, the CD59 positive 
control and the CD99 negative control. The α-chain (CD25) reveals the weakest 
release of 57 % compared to 84 % of β-chain (CD122) and 73 % of γ-chain 
(CD132). However, despite of the only weaker release of the α-chain (CD25) 
compared to the β-chain (CD122) and the γ-chain (CD132), this experiment shows 
a significant decreased signal which let us conclude that the modified receptors 
show a clear-cut GPI-anchoring. The CD59 is a naturally GPI-anchored molecule 
and is therefore used as positive control which reveals a release of 93 %. The 
CD99 is a naturally transmembrane receptor, and is therefore not released by the 
PI-PLC (release 1%). The controls CD59 and CD99 give a hint, concerning the 
specificity of the PI-PLC release. 
The PI-PLC release experiments show that the developed constructs that we use 
in our experiments are to a significant amount GPI-anchored. 
 
 
3.4.4 Fluorosomes decorated with Interleukin-2 stain human 
embryonic kidney-293 cells transfected with Interleukin-2 
receptor-components  
 
After having shown on HT-2 cells that it is in principle possible to visualize 
receptor-ligand interactions using fluorosomes (FS), we wanted further to assess, 
if we could also detect different binding affinities. 
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For that purpose, we have Ca2PO4-transefcted HEK-293 cells with different chain 
combinations, the intermediate-affinity receptor (βγ-chain) and the high affinity 
receptor (αβγ-chain), of the IL-2 receptor and stained them with IL-2::GPI MA::GFP 
FS (IL-2::GPI FS) to evaluate their binding capacity. The HEK-293 read out cells 
were prepared three day after transfection for the flow cytometry analyses by 
setting the cell number to 5 x 106 cells per ml. The MA::GFP stable producer cells 
were transfected with gag/pol (OGP) and IL-2::GPI. The secreted IL-2::GPI FS 
were purified from the supernatant, incubated for 30 minutes with the readout 
cells, washed once with FACS buffer and analyzed by flow cytometry. 
 
 
 
Figure 16. IL-2::GPI FS discriminate between target cells expressing low- or high-affinity IL-2 
receptor. (A) Panel shows overlay histograms of HEK-293 cells transfected with control plasmid 
(upper panel), IL-2 receptor βγ-chain (middle panel) or IL-2 receptor αβγ-chain (lower panel) 
stained with either IL-2::GPI (solid line) or control (dotted line) FS. (B) Geometric MFI-values of 
indicated HEK-293 cell transfectants stained with IL-2::GPI (black bars) or control (white bar) FS 
from three independently performed experiments + SD are shown. Statistical significance was 
calculated by the paired, two-tailed Student’s t-test; *** p < 0.001.  
 
 
As stated above, the main question of the experiment is: Are we able to detect 
different binding affinities with the help of IL-2::GPI decorated fluorosomes? The 
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overlay histograms (Fig.16) document the binding difference of IL-2::GPI FS on 
HEK-293 cells transfected with intermediate- or the high-affinity receptor.  
This experiment mirrors the natural affinities of the IL-2 receptor. While control-FS 
show no signal and βγ-transfected HEK-293 cells show an intermediate binding 
affinity the αβγ-transfected HEK-293 cells yield a high affinity signal (Fig. 16A). 
The results of three independent experiments are summed up in Figure 16B 
showing the differences in geo MFI of the used FS preparations.  
In conclusion, the staining results validate the possibility to distinguish between 
cells expressing intermediate and high affinity receptors using FS. We can show 
very important characteristic of interleukin decorated FS: they cannot only detect 
single-chain receptors, they offer the possibility to detect cells expressing different 
states of multi-component receptors and distinguish between them.  
 
3.4.5 Fluorosomes decorated with different Interleukin-2 receptor 
components stain Interleukin-2::GPI transfected human 
embryonic kidney-293 cells 
 
The next question was, if it would be possible to perform the experiments 
described vice versa.  
For that purpose we used fluorosomes (FS) decorated with IL-2 receptor 
components to stain HEK-293 expressing IL-2::GPI. We transfected HEK-293 with 
IL-2::GPI, and cultured them for three days, detached them and set them to a cell 
number of 5 x 10 6 cells per ml. For FS production stable HEK-293 MA::GFP cells 
were transfected with gag/pol (OGP) and different receptor combinations. Four 
different preparations were generated: control FS, FS decorated with the low 
affinity IL-2 receptor (β-chain::GPI), FS decorated with the intermediate (βγ-
chain::GPI) and high-affinity IL-2 receptor (αβγ-chain::GPI).  
Thus transfected MA::GFP cells were cultured for three days and FS, were purified 
and used for staining from the supernatant. The IL-2 decorated HEK-293 read out 
cells were incubated with the respective FS preparations for 30 minutes at RT, 
washed with FACS buffer and analyzed by flow cytometry.  
As expected from the different published binding affinities, the results of Figure 17, 
show also variation in the binding of the respective FS preparations to IL-2::GPI 
transfected read-out cells. The staining intensities can be distinguished between 
low signal only from the γ-chain::GPI FS, intermediate signal from βγ-chain::GPI 
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FS and high signal from the complete receptor (αβγ-chain::GPI FS) (Fig. 17 A). 
The Figure 17B shows the statistical analyses of three independently performed 
staining experiments. This abstract model system confirms that we are able to use 
FS as platform for multi-protein complexes and receptors, because interleukin are 
not physiologically cell membrane associated. 
 
 
 
 
 
 
 
Figure 17. FS decorated with complex combinations of the IL-2 receptor bind to target cells 
expressing membrane-bound IL-2. (A) Panel shows overlay histograms of HEK-293 cells 
expressing membrane-bound IL-2::GPI, which were incubated with control FS (upper panel), IL-2 
receptor γ-chain::GPI FS (upper-middle panel), IL-2 receptor βγ-chain::GPI FS (lower-middle 
panel), or IL-2 receptor αβγ-chain::GPI FS (lower panel), respectively (bold lines). Dotted lines 
represent fluorescence of control transfected HEK-293 cells incubated with the respective FS. (B) 
Geometric mean fluorescence values of IL-2::GPI (black bars) or control (white bar) HEK-293 
transfectants stained with the indicated FS from three independently performed experiments + SD 
are shown. Statistical significance was calculated by the paired, two-tailed Student’s t-test; ns p > 
0.05; * p < 0.05; *** p < 0.001. 
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3.5 Identification of human peripheral blood cells with 
fluorosomes 
 
3.5.1 Interleukin-2::GPI fluorosomes identify activated human 
peripheral blood cells expressing Interleukin-2 receptor α-chain 
(CD25) 
 
In this part of our work we wanted to know, if it is possible to identify receptor 
expression on peripheral blood cells of healthy donor which were activated with 
anti-CD3/CD28 coated beads. 
 
 
 
Figure 18. IL-2::GPI FS identify activated T lymphocytes. Two-parameter dot plot analyses of 
freshly isolated (A) or activated (CD3/CD28 coated beads, 48 hours) (B) PBMC upon incubation 
with IL-2::GPI FS, control FS, or CD25 FITC-conjugated mAb and counterstained with a CD3 APC-
conjugated mAb are shown. Gating for lymphocytes was performed according to typical FSC/SSC-
characteristics. Markers were set according to non binding control mAb or control FS. Data are 
representative of three experiments. 
 
 
 
For that purpose, we first tried to verify if is it, possible to stain directly isolated 
human blood cells. The cells used for the experiment are peripheral blood 
mononuclear cells (PBMC). The PBMC fraction contains lymphatic cells like T and 
B cells and monocytes and are directly isolated from human blood. In primary 
experiments resting and activated PBMC were used. In order to stimulate up 
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regulation of CD25 and thus gain a better read-out for staining with IL-2::GPI 
MA::GFP FS (IL-2::GPI FS). The resting PBMC were used as negative control. 
PBMC were activated with anti_ CD3/ CD28 coated beads and cultured 48 hours 
before the experiment. The beads (3 beads/cell) lead to activation of the T cell by 
inducing the first signal with anti_CD3 and the second signal with anti_CD28. The 
activation time of 48 hours is important for the PBMC as this is the optimal time-
point for the up-regulation of the IL-2 receptor α-chain.  
Proper activation was checked by microscopy of resting PBMC compared to 
activated PBMC and revealed for activated cells clustering and high cell number. 
Staining of the IL-2::GPI FS on resting and activated PBMC was compared to α-
chain (CD25) stained resting and activated PBMC. 
In order to add a better resolution to detection, we used an anti_CD3 antibody to 
specifically stain T cells. In a double staining of resting PBMC we can thus detect 
an upper T cell population that is positive for CD3 and negative for the IL-2 
receptor. In contrast, activated T cells should be double positive in a dot plot, for 
CD3 and the IL-2 receptor. 
Figure 18A shows that resting CD3+ T cells are negative for control FS and 
anti_CD25 and IL-2::GPI FS. The anti_CD25 control antibody, but also the IL-
2::GPI FS reveal a small T cell population of CD25 receptor positive cells, which 
are presumably regulatory T cells (Treg). T cells always contain small amounts of 
Treg. The important feature of these cells is their constitutive IL-2 receptor 
expression, which allows them to become potent consumers of IL-2. (121)  
Figure 11B shows that activated CD3+ T cells shift in the dot plot when using either 
the anti_CD25 antibody or IL-2::GPI FS. The side scatter (SSC) and the forwards 
scatter (FSC) gate for the proliferating T cells was changed because of the new 
cell morphology induced by activation which leads to a different cellular 
autofluorescence.  
These experimental results of the PBMC staining reveal clear-cut staining by FS, 
comparable to staining with antibodies. Moreover, the decoration with IL-2 offers 
the possibility for detection of other cell populations that are not detectable by 
staining for one chain of the IL-2 receptor like the anti_CD25 antibody. This let us 
to the conclusion that the FS staining method will offer new detection and 
interpretation levels.  
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3.5.2 Interleukin-7::GPI fluorosomes identify resting human peripheral 
blood cells expressing Interleukin-7 receptors 
 
In a new step we wanted to know if it is possible to use other Interleukins. Different 
Interleukins will give the opportunity to stain cells that have other receptors as 
marker. Interleukin-7 was chosen for the decoration of the FS. The IL-7 molecule 
has all suitable criteria for the decoration of FS, it has a high affinity to it`s receptor 
and is an interleukin with well-described role, for example in T and B cell 
development and homeostasis. (99, 112-114)  
For these purpose we assessed IL-7 decorated FS using resting PBMC as read-
out cell. The isolation of PBMC from whole blood from healthy donors was 
performed as usual, but PBMC were not activated with beads. The IL-7::GPI 
MA::GFP FS (IL-7::GPI FS) were produced similar to IL-2::GPI MA::GFP FS (IL-
2::GPI FS), by the transiently transfection of stable HEK-293 MA::GFP cells with 
gag/pol (OGP) and IL-7::GPI followed by purification three days after transfection. 
Staining and analyses were performed as described in Material and Methods.  
 
Figure 19. IL-7::GPI FS identify activated T lymphocytes. Two-parameter dot-plot analyses of 
whole blood cells gated on lymphocytes of a representative healthy donor incubated with IL-7::GPI 
FS, control FS or CD127 PE conjugated mAb and counterstained with CD3 APC-conjugated mAb 
are shown.Lymphocytes were gated according to typical FSC/SSC characteristics. Data are 
representative of four experiments. 
 
The IL-7 receptor is composed of two chains, the CD127 and the common γ-chain 
(CD132). Thus we used an anti_CD127 antibody as positive control.  
Both cells the positive control and IL-7::GPI FS show a clear-cut staining of the IL-
7 receptor compared to the negative control FS (Fig. 19). The direct comparison 
between the IL-7::GPI FS and the anti_CD127 shows a stronger staining of the 
antibody. However, the detection of the IL-7 receptor with the IL-7::GPI FS is 
possible and clearly distinguishable from negative control FS. Moreover, the IL-
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7::GPI FS also seem to detect another cell population that are CD3/CD127 
negative but express an IL-7 receptor. The specific binding of the IL-7 decorated 
FS could be shown by experiments using soluble IL-7 as competitive inhibitor for 
FS binding (data not show). 
 
3.5.3 Interleukin-2::GPI fluorosomes identify malignant B cells in 
human peripheral blood cells of chronic lymphocytic leukemia-
patients 
 
The last part included experiments which show FS used in a diagnostic context. 
Therefore we decided to stain chronic lymphocytic leukemia (CLL) B cells with IL-
2::GPI FS. B cells from many CLL patients express the IL-2 receptor on the cell 
surface. One of the characteristic markers for the routine detection of CLL, 
therefore is CD25.  
 
Figure 20. IL-2::GPI FS identify CLL B cells. Whole blood of a CLL-patient was stained with IL-
2::GPI FS, control FS or CD25 FITC-conjugated mAb and counterstained with a CD19 APC-
conjugated mAb. Lymphocytes were gated according to typical FSC/SSC characteristics. Markers 
were set according to staining of non binding control mAb or control FS. Data are representative of 
multiple individuals (n=11). 
 
Detection of CLL B cells was done directly in whole blood with IL-2::GPI FS which 
means that the PBMC were not isolated compared to the other experiments 
described above. We did not know, if our FS system would work in this case. 
However whole blood staining protocols with antibodies are used routinely in 
diagnostic laboratories. Staining of whole blood samples contains some critical 
steps for FS, for example the lysis of the erythrocytes. This lysis step, using LYSE-
solution which leads to the remove of erythrocytes, in whole blood staining 
procedure, could be problematic for the FS. The LYSE-solution could probably 
degrade the FS. Another problem could be reactivity of some blood components 
with the FS which could have a negative influence on the staining result. 
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However, the procedure for the whole blood staining is less complex compared to 
the staining of isolated PMBC. 
For this purpose blood samples were incubated for 30 minutes at RT with the 
anti_CD25 antibody and IL-2::GPI FS. Afterwards the lysis step with LYSE-
solution was performed followed by wash step with bi-distillated water (ddH20) and 
was analyzed by flow cytometry. For the specific detection of the B cells in the 
whole blood staining an anti_CD19 antibody was used. CD 19 is a component of 
the complement receptor and specific marker for B cells. (69,70) 
Figure 20 shows one staining of a representative CLL-patient. The positive control 
antibody and the IL-2::GPI FS shows a clear-cut binding to CD19+ cells in the dot 
plot compared to control-transfected FS. This experiment proves that B cell blasts 
from CLL-patients can be clearly detected with IL-2::GPI FS. The staining of the 
patients was done by routine protocols, which demonstrates the simple handling of 
our staining tool. In general it does not seem as if there are unexpected 
interference with whole blood components or staining reagents components. 
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4 Discussion  
 
The most important coordinated response against infectious microbes is provided 
by the immune-system (70). Moreover, it represents one of the best organized 
systems developed during evolution. The complexity of the system is not only 
marked by its memory capacity but also by its adaptivity, which leads to the 
production of antigen-specific antibodies. (69, 70) Antibodies are remarkable 
molecules concerning their diversity and their specificity, which allows the 
recognition and the binding of an enormous range of antigen. (70) These 
properties of antibodies are the reason for their broad diagnostic application, which 
allows to detect specific epitopes on cells or tissues. The disadvantages of 
antibodies as staining tools are their production which is connected with some 
difficulties. One problem is the usage of animals as producer organism, which is 
time-consuming and ethically problematic. Typical producer animals are rabbits, 
mice or rats. The production method of monoclonal antibodies with known 
specificity in animals was first described by George Köhler and Cesar Milstein 
1975. (70) This technique of antibody production requires purified antigens, which 
is injected into the producer organism. (70) Polyclonal B cells are first isolated 
from the spleen of the producer organism and afterwards immortalized by fusion 
with a mutant myeloma line, which leads to an immortalized hybridoma cell line. 
(70) These hybridoma cells are screened for the production of monoclonal 
antibodies. (70) The input of work required for the production of fluorosomes (FS) 
and antibodies is not comparable. Our complete production is based on in-vitro 
cell culture and does not require stock breeding with animals. The production of 
FS requires only the stable HEK-293 MA::GFP cell line, the retroviral core proteins 
(e.g. MoMLV gag/pol) and the respective immune-receptors. The purified FS can 
be used like antibodies and they also have a high degree of stability.  
There also exist other staining tools basing on the same principle that were 
presented in the past. One of these are Moloney murine leukemia viruses with SU 
protein which is fused the GFP (SU-GFP). (134) The fluorescent dye is targeted 
into the lipid raft and incorporated into the infectious virus. This staining tool was 
used to show virus infection of target cells. The fluorescent VLP developed in our 
laboratory are used in another context: we want to show specific binding of the FS 
to the target cells. But we can say that our tool is an improved version compared 
to above described infectious SU-GFP MoMLV. The FS developed in our 
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laboratory contain an anchor for the fluorescent dye in the inner leaflet of the VLP 
and is not exposed on the outer leaflet like the SU-GFP. (134) The exposed SU-
GFP could be problematic in our system as it would interfere or even inhibit 
receptor/ligand interactions. 
Another derivate of our system are decorated VLP from MoMLV with GFP fused to 
a GPI-anchor. (136) In contrast to SU-GFP MoMLV the second possibility of 
targeting GFP has the advantage that the produced particles are non-infectious. 
The disadvantage of GFP::GPI is the exposition in the outer leaflet of the VLP, 
which is problematic.  
Another staining tool that was shown in past were GFP conjugated interleukins or 
interleukins that were directly labeled with fluorescent dyes. (135) These 
interleukins give also the possibility to show interactions between receptor and 
corresponding ligand. The main disadvantage of conjugated interleukins is the low 
signal intensity. The signal intensity which is emitted by the FS is relatively high 
because of the big VLP platform which contains a large amount of fluorescent dye. 
Moreover, this platform allows us not only to enhance the signal, but also to target 
multi complex molecules. 
Our experiments demonstrate that our newly developed, FS - based system allows 
the staining of different cells, which express the specific ligand on the cell surface.  
In a first step we showed the preferential targeting of MA::GFP to the cell 
membrane of transfected HEK-293 cells, while GFP was mostly equally distributed 
in the cytosol of the cell. For that purpose we used microscopy analyses (Fig.8) 
and biochemical analyses (Fig.9). The microscopy results show a localization of 
GFP to the membrane in the case of the MA::GFP stable producer cells. The 
biochemical analyses using isopycnic sucrose gradients, which separates the cell 
components due to their density gives us the evidence for the targeting of the 
MA::GFP to the lipid raft fractions. Furthermore, the other components like IL-
2::GPI and gag/pol (OGP) were also successfully shown to be targeted to lipid 
rafts due to isopycnic sucrose gradient analyses (Fig.9). Thus, we have clearly 
demonstrated the lipid raft targeting of our components, which is the main 
condition for budding into the FS. 
The next step was to test the staining efficiency and the specificity of the IL-2::GPI 
decorated MA::GFP FS also compared to IL-2::GPI decorated GFP FS. These 
experiments confirmed the high staining efficiency and also the specificity of IL-
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2::GPI decorated FS, which was demonstrated in inhibition experiments using 
soluble IL-2 (Fig.10). We decided to perform these experiments using HT-2 cells 
expressing constitutively the mIL-2 receptor on the cell surface which give us a 
stable read-out and make us independent of transfection efficiency. Therefore, this 
cell line was important to develop the system and perform primary experiments.  
The next interesting point for us was the evaluation of particle stability. We tested 
two major parameters, time and temperature stability. Evaluation of these 
parameters is the prerequisites and at the same time possible barriers for further 
experiments with the FS. The reason why we gave the stability experiments such 
an important role is the application in routine diagnostics, which requires high 
fidelity of the staining tool. Our stability experiments (Tab. 11 and 12) reveal that 
fluorescence activity and staining intensity remain virtually the same when FS are 
stored at 4 °C. Moreover particles seem not to lose activity after freezing at – 80 
°C.  
A further idea was to test differences in binding affinity. For that purpose we set up 
a model system either by the decoration of FS with IL-2::GPI on HEK-293 with 
receptor-components (Fig.16) or FS decorated with receptor-components on IL-
2::GPI transfected HEK-293 (Fig.17). Both experiments revealed differences in FS 
binding, which give a hint about the binding specificity and affinity. However, we 
showed the difference of the binding affinities between the intermediate- and the 
high- binding affinity IL-2 receptor. We discovered that IL-2 receptor-components 
transfected HEK-293, with the intermediate (βγ-chain) and the high affinity 
receptor (αβγ-chain) can be distinguished with the help of IL-2 decorated FS. The 
reached geo MFI of 50 for the intermediate affinity IL-2 receptor and a geo MFI of 
150 for the high affinity IL-2 receptor revealed this clear-cut difference in the 
binding affinities. Moreover, we were able to see this difference, the other way 
round. Interleukin-2::GPI transfected HEK-293 were stained with decorated FS 
with the low affinity (γ-chain::GPI), the intermediate (βγ-chain::GPI) and the high 
affinity (αβγ-chain::GPI) receptor. The result of the stainings were comparable to 
the experiment shown in Figure 16. The low affinity receptor reveals almost no 
significant signal. The intermediate chain leads to a geo MFI of 50 and the high 
affinity receptor to a geo MFI of 100. The last but most relevant experiment is the 
staining of PBMC from healthy and CLL patients with IL-2 and IL-7 decorated FS. 
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The staining of human blood cells is one of our main aims, because this may lead 
to diagnostic application of FS.  
At first we analyzed if it is possible to detect the expression of the high affinity IL-2 
receptor on activated and non-activated PBMC isolated from healthy donors with 
IL-2::GPI decorated FS (Fig.18). Activation of T cells using CD3/CD28 coated 
beads, leads to an up-regulation of the IL-2 receptor α-chain (CD25) which can be 
visualized with IL-2::GPI FS. This leads to a shift of CD3+ T cells in the dot plot 
(Fig.18). Isolated PBMC used in this experiment do not contain other blood 
components like erythrocytes or serum proteins, which could have negative effects 
on the staining results. The next step was to stain PBMC from whole blood 
samples from CLL patients. The CLL patients´ malignant B cells are often IL-2 
receptor positive. One characteristic marker used in diagnostic laboratories for the 
detection of CLL is CD25. Our routine laboratory has a long standing experience in 
the diagnosis of CLL patients, which gave us the opportunity to test different CLL 
patients blood stained with IL-2::GPI FS and standard reagents. The staining of 
the CLL B cell (Fig. 20) of one representative individual is shown, and indicates a 
clear position for both, the anti_CD25 antibody and IL-2::GPI FS. The detection of 
CLL B cells could be a first step to a diagnostic application of FS. 
We showed also the detection of target cells with a second cytokine on FS. 
Staining of isolated resting PBMC was performed using IL-7::GPI decorated FS. 
(Fig. 19) These staining result showed strong binding of IL-7::GPI FS to CD3+ T 
cells and demonstrates that FS can be decorated with a range of molecules. We 
also performed inhibition experiments with soluble IL-7 which leads to an inhibition 
of IL-7::GPI FS binding (data not shown). The inhibition indicates that the binding 
of IL-7::GPI FS is specific. 
In summary, our experiments demonstrate the efficient lipid raft targeting of our 
constructs and the specific binding and high staining intensity of FS. Furthermore, 
we showed that FS are stable over time and at various storage temperatures and 
that it is possible to decorate FS with multi-subunit receptors and to stain different 
target cells.  
Further potential applications of our particles could be the characterization of so 
far unknown receptor ligand interactions. Furthermore, the VLP platform can 
accommodate multi-subunit ligands or receptors, which are otherwise not easy to 
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express in the appropriate configuration and thus offers new perspectives for 
detection. 
Disadvantages of our system are at the moment the transmembrane protein 
classes, while we are obligated to use derivates of type I transmembrane because 
of their orientation in the cell membrane. These proteins have to be liked to GPI-
anchor to make sure that the transmembrane proteins are targeted into the lipid 
rafts. Another problem is the complexity of the FS, which is composed of different 
molecules and which might be problematic for the particle stability. Stability 
problems were, however, ruled out by the evaluation of the FS stability over the 
time which reveals that staining activity is assured for three weeks. Also the virus 
particle could be problematic because the virus envelope could probably interact 
with cell components and lead thereby to incorrect results. 
In the future, we also hope to develop convenient expression strategies for type II, 
III and IV transmembrane proteins suitable for the membrane environment of FS. 
Moreover, it will be interesting to explore the possibility to establish multicolor FS 
for double or triple staining purposes. The recently described ‘fruit’-colors 
developed by Roger Tsien and co-workers appear to be interesting candidates in 
that respect. (5) Another interesting point will be the direct staining of tissues with 
the FS that could be detected in microscopy.  
Antibodies are very common and well established staining tools. However, we 
hope to supplement these detection systems with our FS. The FS possess all 
properties for a valuable staining tool, that can be easily meet the requirements to 
modified detected target cells of choice. 
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